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EXECUTIVE SUMMARY 
 
This report presents the findings of a study to elicit societal preferences for quality adjusted life year 
(QALY) gains from health care interventions. The aim was to elicit societal preferences across three 
characteristics: (1) burden of illness (BOI) from a medical condition given current health care 
interventions (i.e. QALY loss per patient from a condition due to both premature mortality measured 
against normal life expectancy and health related quality of life (HRQoL) below one), (2) therapeutic 
improvement (TI) (i.e. whether preferences for large QALY gains are disproportionately larger than the 
size of the gain), and (3) end of life (EOL) (defined by the National Institute for Health and Care 
Excellence (NICE) to be expected survival of less than 2 years and expected survival gain of 3 months or 
more, though survival is also examined as a continuous variable).  
Methods 
After undertaking a series of preparatory studies, a survey using Discrete Choice Experiments (DCE) was 
conducted with an online general population sample using an existing panel. Respondents were asked 
to choose whether to treat patient group A or B, who differed in terms of four attributes: life 
expectancy without treatment, survival gain from treatment, HRQoL before treatment and gain in 
HRQoL from treatment. These four attributes are used to derive the BOI, QALY gain and survival (or 
EOL). No indifference option was given. There were four different variants of the questionnaire, each 
having a different normal life expectancy (5, 20, 40 and 80 years) with each respondent making 
comparisons between groups with the same normal life expectancy.  
The DCE was designed using a D-optimality algorithm which generated 580 pairs allocated across 58 
blocks with each respondent completing one block, i.e. 10 DCE questions. The choices between 
treatment pairs A and B were analysed using conditional logistic regression with a range of 
specifications to estimate coefficients for the characteristics of BOI, QALY gain, and EOL. The robustness 
of the results across the four normal life expectancies and their sensitivity to various exclusions was 
examined.  
Results 
There were 3,669 respondents who completed the survey from an online panel. Although an age 
distribution similar to the UK general population was achieved, there were some differences in other 
characteristics. The majority spent less than 30 minutes completing the survey which comprised of: a 
video introduction, two practice questions (one question where one profile is dominant in QALY gains 
and the second question where one profile is dominant in BOI), 10 DCE tasks, nine questions on 
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attitudes to giving priority to patients on the basis of treatment gain, severity of illness and length of 
survival, and 17 questions on the health, socio-demographics and understanding of the respondent.  
The practice questions indicated a strong preference for a larger QALY gain and a weak preference for 
favouring those with a larger BOI (all else being equal). In the practice question the proportion of all 
respondents choosing to treat the patients with higher BOI was 50.8%, yet following the exclusion of 
respondents who misunderstood the DCE task, the proportion choosing to treat the patients with higher 
BOI was 63.5%. There were other questions in the survey with one dominant or near dominant profile in 
terms of BOI (34 pairs) that also provided support for BOI. Analyses of these revealed a majority of 
respondents typically choosing the group with the higher BOI at 52-85%. This supports the overall 
finding that BOI does have a positive impact overall. 
Regression results indicated that survey participants preferred to treat patients who had larger QALY 
gains, but at a diminishing rate and there was no support for TI. They also preferred to treat patients 
who had a shorter life expectancy or who were at the EOL. The results for BOI were less robust across 
alternative model specifications, but suggested some support for BOI. Excluding respondents who 
misunderstood the DCE task, regressions estimated positive, significant and robust coefficients for BOI. 
The attitudinal questions seemed to broadly support these findings. They indicated limited support for 
giving priority to treating those who were very ill. There was widespread support for treatment gain, but 
a similar number of respondents wanted to give an equal priority to all patients. The support for EOL 
was only significant where life expectancy was below normal or they had a good health status following 
treatment. These attitudinal questions must be treated with caution since they do not explore 
respondent’s willingness to trade.  
Discussion 
At the start of the study the hypotheses were that BOI, TI and EOL would have a positive effect on 
preferences. The results indicate modest support for BOI as a consideration when weighting QALYs. The 
evidence did not support the idea of therapeutic improvement. There was robust and consistent 
support for EOL in general, though responses to the attitudinal questions did not support EOL. Overall 
there seems to be a strong preference for larger QALY gain but at a diminishing rate. These results 
support the argument that the social value of a QALY is not equal between recipients, but depends on 
the burden of their condition and expected survival.  
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1 INTRODUCTION 
 
Economic evaluation is used to inform decisions related to setting priorities in health care and whether 
health care interventions should be reimbursed. A widely used method is to enumerate the cost 
effectiveness of an intervention in terms of the incremental cost per Quality Adjusted Life Year (QALY) 
and compare this to some threshold cost per QALY to reflect displaced activities.[Claxton et al, 2013] 
The approach is designed to improve the efficiency of health care spending and typically assumes that a 
QALY is worth the same regardless of who gets it. However, agencies that use cost per QALY in their 
decision making often take other factors into consideration explicitly or implicitly.[Devlin and Parkin, 
2004] It has long been recognised that the QALY approach can incorporate a more complex algorithm 
than simply assuming ‘a QALY is a QALY’.[Weinstein, 1988] At the same time there is emerging evidence 
that members of the public can weight some QALY gains more highly than others, depending on who 
receives them.[Green, 2009; Shah, 2009; Brazier et al, 2007; Nord, 2005; Linley and Hughes, 2013] 
The literature has uncovered a broad range of attributes across which the value of QALYs may be 
expected to vary, including: age, health state before treatment, the size of the health benefit, socio-
economic background of a typical patient, degree of responsibility, and broader notions of 
fairness.[Keetharuth et al, Forthcoming] For an attribute to be used in cost per weighted QALY analysis 
it needs to be supported by normative argument and empirical evidence to quantify its size. The 
empirical basis can be surveys of the general public on the grounds that they are potential tax payers or 
on the basis of democracy. It could also be argued that the views of politicians may be appropriate since 
they have a democratic mandate. Most research has been undertaken with members of the general 
public and this suggests that the general public does not always favour the view that all QALYs are of 
equal value. The main idea to emerge from the literature is that those in worse health should be given 
greater priority than those in better health, often referred to as the severity argument, though this is 
not found in all studies.[Shah, 2009] 
An important consideration is the way severity is defined and measured. The earlier literature tended to 
focus on severity in terms of the health state of the recipient before treatment. Work by Nord and 
others looked at the relative weighting of an improvement in health, say from 0.2 to 0.4 on the 1-0 full 
health-dead scale compared to 0.8 to 1.0.[Nord, 1993; 2005] In a number of studies it was found that 
respondents often gave more weight to gains at the lower end of the scale. However, this is quite a 
narrow notion of the severity of a condition, or more generally of someone’s health profile. The severity 
of a condition is typically seen in terms of mortality as well as the quality of their state of health. As 
argued by Hansson and colleagues [1994] “Severity of disease can be defined as prognosis without 
treatment, i.e. expected remaining life years adjusted for the quality of life for these years’’.[page 353] 
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They went on to argue: “This implies that the same metric (such as Quality Adjusted Life Years or QALYs) 
can be used for comparisons of outcomes with and without treatment. If health benefit with treatment 
is measured along the axes of mortality, pain, physical, mental and social functions, so should severity of 
disease.”[Hansson et al.1994, page 353] It could be argued further that equity considerations should be 
incorporated over a person’s whole health profile and not simply starting from today. This is the basis of 
a fair innings criterion, whereby the weight of a QALY for a given recipient depends on what has gone 
before and what will happen without treatment compared to some expectation or target level of 
survival and health state over time.[Williams, 1997] However, decisions are made for the future and it 
could be argued that prospective health should be the focus for decision making.[Nord, 2005] 
The research reported in this paper attempts to operationalise the notion of severity of disease set out 
by Hansson and colleagues[1994] using a metric that is compatible with the cost per QALY analysis used 
by National Institute of Health and Care Excellence (NICE).[2013] The research was commissioned by the 
UK Department of Health’s Medicines, Pharmacy and Industry group. In a consultation document, the 
English Department of Health (DH) set out a new mechanism for pricing drugs in the UK known as Value 
Based Pricing (VBP).[Department of Health, 2010] The proposed new mechanism will assess the cost-
effectiveness of medicines by taking into account a wider scope of value, including the severity of 
disease and wider societal benefits.[Department of Health, 2010] The consultation specified severity in 
the terms set out by Hansson et al.[1994] and referred to this as burden of illness (BOI). BOI is measured 
using the outstanding QALY loss suffered by patients with current treatments.  
The consultation document proposed another criterion based on the size of therapeutic improvement 
(TI) to reflect the benefits of those innovations that bring about a ‘step change’ in outcome for patients. 
This criterion implies that larger sized gains per recipient should be weighed more highly than smaller 
gains over more recipients. This has been examined in the literature in terms of whether a given benefit 
of health should be concentrated for the benefit of ‘a few’ or dispersed more widely to the ‘many’. The 
evidence on this attribute is mixed, with respondents often favouring greater dispersion.[Olsen, 2000] 
However, there is some evidence to suggest that there may be a threshold below which a given QALY 
gain has proportionately less value. For example in Dolan et al.[2008] respondents tended to prefer to 
disperse life years until a threshold of 2.6 years, whereas in Rodriguez-miguez and Pinto Prades[2002] 
there was a threshold at 9.1 years. The precise threshold is likely to depend on the context, but research 
into concentration versus dispersion provides some support for this idea of TI. 
Finally, this work was being undertaken in the UK policy environment where there already exists 
another attribute that is used in health technology assessment (HTA) appraisals. This is the ‘end of life’ 
(EOL) supplementary criterion used by NICE which stipulates that a greater weight can be given to QALY 
gains where the recipients have a life expectancy of less than two years and a survival gain of 3 months 
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or more (provided the condition is a ‘rare’ disease).[NICE, 2009] Therefore this attribute has been 
included in the current research. 
The aim of the research presented in this report was to inform the development of VBP in the UK by 
eliciting societal preferences for the following attributes of interest to DH: 1) BOI given current health 
care interventions – defined as the QALY loss per patient from a condition due to premature mortality 
and morbidity measured against normal life expectancy and reduced health related quality of life, 2) TI - 
whether preferences for large QALY gains are disproportionately larger than the size of the gain, and 3) 
EOL - defined by NICE to be expected survival of less than 2 years and a survival gain of 3 months or 
more,[NICE, 2009] though survival is also examined as a continuous variable. The methods developed 
for operationalising these attributes, the survey to elicit the preferences of the general public using a 
discrete choice experiment and the analysis that was undertaken are presented. The results are detailed 
together with a discussion of their implications for health care policy and research in the field.  
 
1.1 Preparatory work 
In order to elicit societal preferences for BOI, TI and EOL the following needed to be determined: 
1) a framework that incorporates BOI, TI and EOL and excludes age of the patient group receiving 
the intervention, 
2) a mode of administration of the survey, 
3) a framing of questions for the survey, and 
4) a comparison of alternative methods and modes of administration of the survey. 
A series of preparatory studies were undertaken to determine 1 to 4. These are described briefly below. 
Readers not interested in the preparatory work should proceed to section 2. 
 
1.1.1 Study 1: Developing a framework 
The first study involved a review on the social value of a QALY to determine the existing understanding 
of societal preferences for a range of attributes.[Keetharuth et al, Forthcoming] The aims of the review 
were to: 1) review the attributes that society values in the literature, 2) provide a shortlist of attributes 
for consideration in the implementation of value based pricing, 3) determine whether any off-the-shelf 
weights exist that could be used, and 4) identify gaps in the literature as a basis for future research to 
enable the successful implementation of value based pricing.  
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Methods 
First, a general search using Medline and Econlit was conducted. Second, a textbook was identified with 
a list of attributes used in the social value of a QALY literature. Third, separate searches were conducted 
using Medline and Econlit using the attributes found previously and their variations as search terms. 
Fourth, an update was carried out with similar terms to those used in the published reviews. Finally, key 
papers known to the authors were included and citation searches of these papers were undertaken. 
 
Results 
Fifteen attributes were identified in the literature. Criteria were used to determine a shortlist of these 
attributes applicable to value based pricing. The main problem was the lack of good quality empirical 
evidence on societal values. Severity was the only shortlisted attribute, yet if more evidence could be 
gathered, an alternative medium list consists of the following attributes: concentration versus 
dispersion of benefits, rarity of conditions, end of life and iatrogenic diseases. No off-the-shelf weights 
exist that are appropriate for implementation in VBP. 
 
Discussion 
It was concluded that since no off-the-shelf weights exist that can be used for BOI, TI and EOL for 
implementation in VBP, research needs to be conducted to elicit societal preferences for these 
attributes. Furthermore, no framework exists that enables the simultaneous consideration of BOI, TI 
and EOL in a societal preference elicitation task.  
 
A framework was developed (explained in detail in section 2.1) that incorporated BOI, TI and EOL and 
excluded age of the patient group receiving the intervention. The framework was based upon the Global 
Burden of Disease (GBD) developed for the World Health Organisation (WHO) and the World Bank using 
a measure called the Disability Adjusted Life Year (DALY).[Murray et al, 1996] The framework is a 
modified version of the GBD based around the notion of QALY loss associated with a condition from the 
point of being considered for the introduction of the new technology (known by NICE as the decision 
point). This methodology is consistent with existing HTA methodology used by NICE as it is based on UK 
mortality and morbidity data using EQ-5D.  
 
A research agenda was agreed with Department of Health to develop a preparatory survey based on the 
proposed framework to elicit preferences for BOI, TI and EOL. 
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1.1.2 Study 2: Developing and testing survey methods 
The second study involved a large preparatory survey to pilot questions designed to elicit preferences 
for BOI, QALY gain and EOL.[Rowen et al, Forthcoming a] The questions were developed using the 
framework developed in study 1 and built upon the methods used in similar surveys undertaken to elicit 
societal preferences for a QALY.[Baker et al. 2010; Lanscar et al. 2011] The aims of the study were to: 1) 
examine the preference elicitation method most suitable for eliciting preferences for BOI, QALY gain 
and EOL, and 2) examine the suitability of the proposed selected design for each elicitation method.  
 
Face-to-face interviews have been most widely used to elicit preferences, but recently there has been 
increased interest in collecting preference data online. Face-to-face interviews are expensive and time 
consuming and as a result often have lower sample sizes but provide high quality reliable data with high 
completion rates. Online surveys enable a large number of responses to be collected quickly and 
relatively cheaply but there is a concern about the quality of the data, as without an interviewer present 
there is no guarantee than the respondent has understood or engaged with the survey. This study used 
an online survey for eliciting preferences for BOI, QALY gain and EOL. 
 
Methods 
A self-complete computer-based survey was developed involving discrete choice experiment (DCE) and 
person trade off (PTO) tasks. Each task involves 2 groups of patients with 2 different conditions, where 
each group has the same normal life expectancy and HRQoL (life expectancy and HRQoL without the 
condition), a different lower life expectancy and/or HRQoL if they have the condition, and a different 
gain from treatment in terms of life expectancy and/or HRQoL. A DCE task asks whether the respondent 
would rather treat 100 patients with condition A or 100 patients with condition B. A PTO task 
determines how many patients with condition A need to be treated to be equivalent in social value to 
treating X patients in condition B, using an iterative procedure. Prior to launching the survey in an online 
environment a small pilot study was conducted of 20 respondents using the online interface in an 
interviewer setting. Subsequently an online survey of 3,000 respondents was conducted using a 
representative sample of the UK general population. At the start of the survey respondents watched a 
video introducing the survey and explaining the concepts involved in their survey. All respondents 
answered a practice DCE question and then respondents answered either a block of 10 DCE questions or 
2 DCE questions followed by 5 PTO questions. Respondents were randomly allocated to a block of 
questions at the start of the survey. Respondents answering only DCE questions saw questions involving 
2 different normal life expectancies; that is, life expectancy without having the condition. Respondents 
answering both DCE and PTO questions only saw one normal life expectancy. Normal life expectancy 
was always the same for both profiles in a task.  
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Each question involved a choice of which group to treat out of two groups with different conditions, 
Condition A and Condition B, and the question included both a text explanation of the scenarios and a 
diagram. Respondents were told that there were 100 patients in each group in the DCE questions. In the 
PTO questions there were initially 100 patients in each group. First, respondents were asked which 
condition they preferred to treat, and then the number of patients in that group was reduced by 10 
patients. This process was repeated until the respondent was either indifferent between each condition 
or switched between treating condition A and condition B. Then the number of people in the condition 
they switched from was increased by 5 patients and the question asked one final time. At the end of the 
survey all respondents were asked 12 questions on their health and sociodemographics. 
 
The scenarios for the DCE questions involved scenarios specifically selected to answer the following: 
• Do respondents prefer to treat the group with the larger QALY gain (where everything else is 
equal across the groups)? 
• Do respondents prefer to treat the group with QALY gains in HRQoL or life expectancy (where 
everything else is equal across the groups)? 
- Is this affected by whether life expectancy is low, middle or high and whether HRQoL is 
low, middle or high? 
• Do respondents treat the group with the largest BOI (where everything else is equal across the 
groups)? 
- Is this affected by whether BOI is in HRQoL, life expectancy or both? 
 
It was hypothesised that respondents would prefer to treat the group with the larger QALY gain, be 
indifferent between gains in HRQoL and life expectancy, prefer to treat the group with the largest BOI 
and prefer to treat the group that were categorised as EOL. 
 
In addition the survey also included a full study design when patients in each condition have 20 years 
normal life expectancy for both the DCE and PTO tasks and a full study design when patients have 5 
years normal life expectancy using the DCE elicitation task. This enabled the estimation of regression 
models for each of the normal life expectancies and models that combine DCE data for normal life 
expectancy of 5 years and 20 years. This approach was undertaken to determine whether regression 
models combining data across different normal life expectancies was feasible and appropriate and to 
compare the results for different normal life expectancies. 
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Results 
The results were as hypothesised regarding overall QALY gain, EOL and QALY gain separated by HRQoL 
and life expectancy, as respondents were more likely to treat the group with the larger QALY gain, were 
more likely to treat the group that were categorised as EOL, and there was no distinguishable pattern 
for choosing gains in health or life expectancy. However, the results did not show that BOI was 
important, in fact it suggested the reverse, where respondents were more likely to choose to treat 
conditions with lower BOI. The results also questioned whether increasing the size of the QALY gain was 
increasingly important to individuals.  
 
Discussion 
Both DCE and PTO tasks were feasible. The full study design for DCE for normal life expectancies of 5 
and 20 years were appropriate but the coefficients in the regression models differed for the different 
normal life expectancies. Study design of the PTO tasks for a normal life expectancy of 5 years proved 
more difficult and the data provided multiple complex challenges for analysis due to the scaling of the 
PTO variable generated by the study design. For this reason the DCE task was selected as more 
appropriate. 
 
The finding that BOI was not important was contrary to the hypothesised results. The survey design did 
not enable the result to be examined further in order to ascertain whether the finding correctly 
reflected respondents’ societal values, or whether respondents misunderstood the concept or the 
question (for example respondents may have chosen which condition they preferred to live in or 
thought was best, rather than which condition they would rather treat). The explanation for the finding 
could not be determined using this survey data alone as no data were collected on respondents’ 
underlying attitudes, or using different framing of questions or a different mode of administration. 
There was a concern that the framing of questions and online setting may have influenced the results. 
 
1.1.3 Study 3: Qualitative study of protocol 
The third study undertook a qualitative survey to further explain the findings of study 2.[Rowen et al, 
Forthcoming a] The aim of this study was to provide information about whether the finding in the large 
preparatory survey undertaken in study 2, that BOI was not important, was due to genuine preferences 
or a misunderstanding of the questions. 
 
Methods 
The study involved qualitative interviews with a small convenience sample of 21 people to examine 
preferences regarding BOI in detail. Respondents completed 8 of the DCE assumption testing questions 
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included in the preparatory survey that asked mainly whether respondents preferred to treat the group 
with the higher BOI. The same online interface as the preparatory survey was used but the interviewer 
was also present in the room. After respondents had answered the DCE questions they were then asked 
open-ended questions about the reasoning behind their responses. The interviewer also explained the 
implications of their choice to the respondent and then asked the respondent whether this information 
meant they wanted to change their choice. A subsample of respondents answered questions that did 
not include the pictures included in the preparatory survey to determine whether this affected 
understanding and choices.  
 
Results and Discussion 
The results from this survey suggested that the finding in the preparatory survey that BOI was not 
important may at least in part be explained by a misunderstanding of the concept and the task. The 
results implied that the framing of the questions was not appropriate as some respondents 
misunderstood the questions. It also raised concerns about the suitability of the online mode of 
administration for this type of survey where there is little means of clarifying the questions to 
respondents or ensuring that they have understood the meaning of their choice. The results of this 
study suggested that further research was needed to develop and test the framing of questions and to 
determine whether an online survey is appropriate for eliciting preferences for BOI, QALY gain and EOL, 
or whether a face-to-face interview is more appropriate where interviewers can repeat explanations 
and monitor understanding and engagement with the survey. 
 
1.1.4 Study 4: A comparison of methods and mode of administration 
The fourth study examined different framings of questions and mode of administration to examine 
which was most appropriate for eliciting preferences for BOI, QALY gain and EOL using the framework 
developed in study 2.[Rowen et al, Forthcoming b] This was due to concerns raised in study 3 about the 
suitability of an online mode of administration and the framing of questions used. The aim of this study 
was to determine the most appropriate mode of administration and framing of questions suitable for 
eliciting societal preferences for BOI, QALY gain and EOL.   
 
Studies 2 and 3 raised concerns about the elicitation of preference data online, and study 3 raised 
concerns about the exact wording and framing effects of questions used to elicit preferences for BOI, 
QALY gain and EOL. There are concerns about the quality of data from online surveys, where 
respondents’ understanding is not easily monitored, yet face-to-face interviews are expensive and time 
consuming for surveys with large sample sizes. Therefore this study compared data collected online and 
face-to-face.  
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 Questionnaire wording is of extreme importance as responses can be affected by the exact wording 
used. Framing effects are well acknowledged in the economic literature but are largely unexplored in 
the elicitation of societal preferences. With a complex topic for the survey, it is important to ensure that 
questions are worded clearly and simply to enable respondents to understand and engage with the 
questions. This study examined different ways of wording the questionnaire. 
 
Methods 
A 6-arm survey was conducted, where 3 arms were administered in an online survey and 3 arms were 
administered using face-to-face interviews. DCE was selected as the preference elicitation technique 
using the results of study 2. Three different framings of questions were used, and each were 
administered using both face-to-face interviews and online. The framing differed by: the inclusion or 
exclusion of pictures to accompany the descriptions of the alternatives; stating the levels of the 
attributes with and without treatment or stating the change in the attributes from the normal level to 
no treatment and from no treatment to treatment; and the labelling of the no treatment, treatment 
and expected health profiles; and by the labelling of the groups. 
 
Each arm used the same questions, only the framing and mode of administration differed. The 
questions were selected to examine whether respondents choose to treat the group with the highest 
treatment gain and BOI, whether respondents systematically choose to treat the group with treatment 
gains in HRQoL or life expectancy, and whether responses were affected by the exact attributes in the 
questions. Respondents were asked which group they would rather treat. The format of the questions 
was simplified compared to the preparatory study, study 2, and included feedback after each practice 
question to assist in understanding the task.  
 
At the start of the survey respondents either watched a short video explaining the questions or in one of 
the arms were read a short introduction by the interviewer. Each arm had 2 practice questions that 
involved a dominant choice, where only treatment gain differed across the alternatives in the first 
practice question, and only BOI differed across the alternatives in the second practice question. Each 
practice question involved a detailed explanation and after making their choice respondents were given 
an explanation of their choice, and asked whether they still wished to treat that patient group. If 
respondents changed their mind, they then started the question again. This process was repeated once 
in the interviewer arms and was repeated up to 7 times in total in the online survey. This process was 
used to ensure that respondents understood the task and understood the choice they made.  
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Following the 2 practice questions in the interviews, respondents completed 7 interviewer-administered 
DCE questions, 9 self-complete questions on attitudes, 11 self-complete questions on EQ-5D and socio-
demographics and then 5 or 6 (depending on the arm) interviewer-administered questions on their 
understanding and what they thought of the survey. The online survey followed the same process but 
all questions were self-complete. At the end of the interview the interviewer reported their perception 
of respondent understanding, effort and concentration. 
 
Responses in all arms were compared to determine whether responses differed by arm to the DCE 
questions, whether responses to the DCE questions were consistent with responses to the general 
attitudinal questions and what respondents thought of the survey. 
 
Results 
In the first practice question, respondents overwhelmingly chose to treat the group with the highest 
treatment gain, varying from 78.3% to 95.7% across arms. In the second practice question results for 
BOI were mixed, where 39.1% to 60.9% chose to treat the group with the higher burden across arms. A 
larger number of respondents in the online arms changed their mind in both of the practice questions 
when provided with an initial explanation of their choice (6.2% and 6.0% for the first and second 
practice questions respectively for respondents in the online arms versus 0% and 4.3% for respondents 
in the interviewer arms).  
 
Responses to the BOI questions demonstrated that respondents did not always choose to treat the 
group with the higher BOI. Respondents did not always choose to treat the group with gains in either 
HRQoL or life expectancy. The results for BOI and treating the group with gains in either HRQoL or life 
expectancy differed by arm, but there was no clear pattern in differences in responses across different 
modes of administration or framing. 
 
Responses to the attitudinal questions indicated that the majority of respondents believed that the NHS 
should give the same priority to treating all patients who are ill, regardless of how ill they are. There was 
limited support for BOI, no or little support for EOL, and some support for treating the group with the 
higher treatment gain. Overall, responses to the attitudinal questions did not differ across the arms. 
 
Discussion 
The mode of administration and framing of questions used in each survey arm was feasible, and 
respondents reported that they found the DCE and attitudinal questions easy to understand. In terms of 
understanding and wording of the questions, there was little to choose between the arms as all modes 
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of administration and framing of questions seemed feasible and appropriate. Respondents reported 
that the video was useful and pictures were helpful in the arms where they were included. The revised 
format of the practice questions which involved additional information and an explanation of the 
respondents implied choice increased the number of respondents making the expected choice. 
 
For the final survey the mode of administration of an online survey was chosen over an interviewer 
survey due to lower cost and quicker data collection. The selected framing of questions contained text 
with pictures since respondents found them helpful and performed similarly to other arms.  
 
2 METHODS 
 
The preparatory studies described above determined the framework of analysis, the elicitation 
technique, and mode of administration and framing of questions. In this section, these aspects of the 
main survey are described in more detail.  
 
2.1 Framework of Analysis 
BOI is measured using the outstanding QALY loss suffered by patients with current treatments. The 
same idea underpins GBD developed for the WHO and the World Bank using DALY measure.[Murray et 
al. 1996] The GBD study measured BOI in terms of loss of life expectancy from premature mortality and 
disability. BOI is represented in Figure 1 as two components: 1) the loss from premature death 
represented by the area A2.A3.A4.A5 and 2) the loss from disability which is the shaded area A1.A2.A5 
between the profile and the line indicating full health.  
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Figure 1: Representation of the WHO Global Burden of Disease 
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The GBD is widely used to indicate the burden of a disease and has been used for many years to inform 
international health policy. The most recent update moved from using expert opinion to general public 
surveys to provide disability weights as well as removed age and time preference weighting which had 
been used in previous estimates.[Salomon et al. 2012] Furthermore, expert groups were used to 
describe conditions in terms of their ‘major functional consequences’, such as the effect on daily 
activities and pain rather than as disability classes for valuation purposes. This brings the disability 
weights more in line with approaches that are used to generate weights for HRQoL measures. However, 
it is based on an international model life table to estimate life expectancy, whereas for UK policy it is 
preferable to use UK mortality data life tables. Second, the disability weights for each condition are 
based on the impact of a given disease rather than using an empirically based method with a common 
measure of HRQoL such as the EQ-5D which is used in HTA in the UK. The measurement of BOI used in 
this study is related to GBD at the level of an individual, except that it is measured from the point at 
which the treatment decision is being considered, such as patients with rheumatoid arthritis who have 
not responded to first line treatment and are being considered for second line treatment. It does not 
consider a person’s previous health.  
 
The proposed methodology is more in keeping with existing HTA methodology currently used in the UK 
by NICE as it can be based on UK mortality and morbidity data using EQ-5D. The components of the 
attributes of BOI, TI and EOL as described in this study are shown in Figure 2. Individuals in this 
population have a health profile without the new treatment, which for simplicity is represented by 
health state (H) and life expectancy (E), and this is assumed to be without treatment. To estimate the 
BOI or QALY loss associated with the condition it is necessary to establish an expected or target level of 
health and life expectancy. The target level of health without the disease is assumed to be 100% with 
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normal life expectancy (N). The expected improvement from treatment is represented by a gain in 
HRQoL (Q) and an improvement in survival (S).  
 
Figure 2: Representation of profile used in survey 
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Where N = normal life expectancy, E = life expectancy without treatment, S = survival gain from treatment, H = 
health before treatment, Q = health gain from treatment 
 
The information presented in Figure 2 includes: 
- Normal health without the condition - HRQoL and life expectancy without the condition 
(100%*N or 1*N where 1 represents full health in utility terms) 
- A+C represents the burden of illness from a shorter life expectancy without treatment i.e. QALY 
loss from premature mortality (BOISU) 
- B+D represents the burden of illness from a poorer HRQoL without treatment i.e. QALY loss 
from morbidity (BOIQL) 
- A+B+C+D represents burden of illness i.e. effect of having the condition without treatment (BOI) 
- C represents QALY gain as a result of gains in life expectancy from treatment (QLYSU). Note that 
the area represented by Q*S is included in these gains from life expectancy rather than those 
from HRQoL as these QALY gains are not possible without extending survival.  
- D represents QALY gain as a result of gains in HRQoL from treatment (QLYQL) 
- C+D represents overall QALY gains from treatment 
- F represents HRQoL and life expectancy without treatment (equivalent to N- BOI) 
- EOL is represented by life expectancy before treatment i.e. E less than or equal to 2 years. 
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2.2 Elicitation technique 
A DCE based on pairwise comparisons was chosen as the method to elicit preferences. DCE was chosen 
since it permits the simultaneous consideration of different attributes in a format that is amenable to 
being administered online. It had also already been successfully employed by Baker and colleagues in 
their social value of a QALY project.[Baker et al, 2010] Each pairwise task asked respondents to choose 
which group they would prefer to treat, patient group A or patient group B. No indifference option was 
given. The profile of normal health without the condition was the same across both patient groups, but 
their health and life expectancy both with and without treatment could vary (Figure 3 shows an 
example using the first practice question). 
 
2.2.1 Selection of attributes and levels 
The profiles of patient groups A and B in each pairwise comparison were generated using 4 attributes: 
life expectancy without treatment (E), survival gain from treatment (S), health before treatment (H), 
health gain from treatment (Q) (see Figure 2). The levels of each of the attributes for different levels of 
normal life expectancy are outlined in Table 1. These were selected to cover a full range of potential 
levels, but ensure precision over the more common interventions in the real world. Some interventions 
are for patient groups involving mainly children and it is possible that such interventions could have 
large QALY gains. However most HTAs conducted in the UK involve interventions used in patients with a 
small number of years of normal life expectancy left with small QALY gains. For example, Walker[2011] 
found that median QALY gains submitted to the Scottish Medicines Consortium (SMC) were 0.097, and 
only 1 intervention in 8 had mean QALY gains greater than 1 QALY. Therefore, additional levels are 
included when normal life expectancy is 5 years (i.e. patients are at the end of their natural life) to 
obtain greater precision for interventions used at the end of life and to obtain precision for the types of 
HTAs often conducted in the UK. The levels of each of the attributes were determined following input 
from the DH. 
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Table 1: Survey attributes and levels 
Attribute Levels Levels Levels Levels 
     
Normal life expectancy, N 
 
5 years 20 years 40 years 80 years 
Life expectancy without 
treatment, E 
3 months  
6 months  
9 months 
1 year  
2 years  
5 years 
3 months  
1 year 
2 years  
5 years  
10 years 
3 months  
1 year 
2 years  
5 years  
10 years  
30 years 
3 months 
1 year  
2 years  
5 years 
10 years  
30 years  
60 years 
Survival gain from 
treatment, S 
0 
1 month 
3 months  
6 months 
9 months  
1 year  
3 years 
0  
3 months  
6 months  
1 year 
3 years 
10 years 
0  
3 months  
6 months  
1 year 
3 years 
10 years 
0  
3 months  
6 months  
1 year 
3 years 
10 years 
60 years 
Health before treatment 
(%), H 
10 20 40 60 80 10 20 40 60 80 10 20 40 60 80 10 20 40 60 80 
Health gain from 
treatment (%), Q 
0 2 5 10 20 30 60 0 2 5 10 30 60 0 2 5 10 30 60 0 2 5 10 30 60 
 
2.2.2 Experimental design 
A full factorial design using the attributes and levels specified in Table 1 would result in a large number 
of possible profiles, meaning it is infeasible to conduct a valuation survey involving every possible 
profile. Profiles were selected using a D-optimality algorithm [Carlsson and Martinsson, 2003; Kuhfeld, 
2005] and the true model was specified in such a way as to allow for the estimation of all parameters of 
interest. Impossible profiles (such as profiles involving a HRQoL gain of more than 100%) were excluded 
from the candidate set for the design. In total the DCE designs constituted 580 pairs of profiles, with the 
number of pairs varying across designs depending on the number of attributes and levels in the design. 
Pairs were allocated into 58 combinations (also known as ‘blocks’) of 10 pairs. Each combination 
contained pairs for one normal life expectancy. Summary statistics of the attribute combinations 
generated by the DCE design are reported in Table 2 for each level of life expectancy. These show the 
large range of QALY gains considered in this survey starting from 0.005 up to 63, and BOI from 1 to 80 
QALYs lost and life expectancy from 0.25 to 60 years.  
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Table 2: Summary of statistics derived from the DCE design 
Normal life expectancy  5 20 40 80 
DCE pairs  160 120 140 160 
      
QALY gain Mean (s.d.) 0.673 (0.744) 2.039 (2.638) 3.012 (4.219) 8.510 (13.64) 
 Median 0.4 0.9 1.2 2.45 
 Minimum 0.005 0.0125 0.005 0.005 
 Maximum 3.4 16 21 63 
      
QALY gain due to survival Mean (s.d.) 0.442 (0.642) 1.417 (2.336) 1.462 (2.389) 5.792 (12.722) 
(QLYSU) Median 0.2 0.4 0.4 0.6 
 Minimum 0 0 0 0 
 Maximum 3 10 10 60 
      
QALY gain due to health Mean (s.d.) 0.231 (0.427) 0.623 (1.205) 1.549 (3.490) 2.718 (6.416) 
(QLYQL) Median 0.075 0.1 0.2 0.3 
 Minimum 0 0 0 0 
 Maximum 3 6 18 36 
      
BOI Mean (s.d.) 4.507 (0.651) 18.518 (1.931) 36.487 (5.449) 73.349 (10.899) 
 Median 4.7 19.2 39 78.4 
 Minimum 1 12 16 32 
 Maximum 4.975 19.975 39.975 79.975 
      
BOI from premature mortality Mean (s.d.) 3.795 (1.23) 16.379 (3.585) 31.335 (10.696) 64.401 (20.582) 
(BOISU) Median 4.25 18 35 75 
 Minimum 0 10 10 20 
 Maximum 4.75 19.75 39.75 79.75 
      
BOI from poor health status Mean (s.d.) 0.712 (0.852) 2.139 (2.482) 5.153 (7.312) 8.948 (13.421) 
(BOIQL) Median 0.4 1 1.8 3 
 Minimum 0.05 0.05 0.05 0.05 
 Maximum 4.5 9 27 54 
      
Life expectancy untreated  Mean (s.d.) 1.206 (1.23) 3.621 (3.585) 8.665 (10.696) 15.599 (20.582) 
(E) Median 0.75 2 5 5 
 Minimum 0.25 0.25 0.25 0.25 
 Maximum 5 10 30 60 
 
2.2.3 Questionnaire design 
Selected attributes and levels were used to design the DCE profiles in terms of life expectancy and 
health before and after treatment. Each scenario in the survey had two profiles representing condition 
A and B with information presented in text as well as using a graph. An example practice question is 
shown in Figure 3. Respondents were asked to imagine there are the same number of patients in two 
different groups, patient group A and patient group B, each with a different medical condition, where 
each medical condition can affect the health of the patients and how long they live. They were told that 
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patients can be treated, but it is only possible to treat one patient group as there are not enough 
resources such as money, staff and hospital space to treat all patients. Respondents were then asked 
which patient group they thought the NHS should treat. Profile information for each patient group was 
presented alongside each other using the following information: 
- Number of years lived from today without treatment - E 
- HRQoL (in %) without treatment - H 
- Number of years lived from today with treatment – E+S 
- HRQoL (in %) with treatment – H+Q. 
 
Participants were not presented with S and Q in the text, though these are easily calculated. There was 
additional information on the level of health (100%) and the number of years that patients would live 
without the medical condition (N). This was a single line of text covering both profiles that was fixed in 
each scenario but varied across questionnaire variants where normal life expectancy changed. There 
were 4 different variants of the questionnaire; each had a different level of normal life expectancy - 5 
years, 20 years, 40 years or 80 years. Normal life expectancy was fixed across all pairs for each 
participant. This was due to concerns that different normal life expectancies would be confusing for 
respondents and would highlight the differences in age of the two profiles, where age is a consideration 
that is not regarded as politically desirable in the UK NHS.[Department of Health, 2012] Each profile also 
had a graph (Figure 3) which provided BOI and QALY information in QALY terms with different colours 
highlighting expected QALYs without the condition, expected QALYs without treatment, and QALY gains 
from treatment.  
 
2.2.4 Survey sample and scenario presentation 
Respondents from an online panel were contacted via email to participate in the survey. Respondents 
were sampled to be representative of the UK in terms of age and gender. At the start of the survey 
respondents read an information sheet and gave informed consent to participate in the survey. 
Respondents were then shown a short video explaining the questions including descriptions of full 
health and less than full health using dimensions and levels of health found in the EQ-5D and the graph 
format illustrated in Figure 3. It could not be guaranteed that respondents watched the video, but the 
video had to be played in full before the respondent could proceed to the practice questions.  
 
The survey had 2 practice questions, each of which involved an explanation of their choice with an 
opportunity for respondents to change their mind multiple times. The first practice question was 
dominant in QALY gains in one profile while all other attributes were the same. The second was 
dominant in BOI in one profile while all other attributes were the same. Figure 3 shows the information 
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displayed on the first screen of practice question 1 with a normal life expectancy of 20 years. Practice 
questions highlighted what individuals should focus on, including the life of each patient group without 
treatment, with treatment and without the medical condition (normal life expectancy and health) in an 
additional box below the scenario (Note: this box was not present in the actual survey scenarios). 
Respondents were also informed that only 1 patient group could be treated. Figure 4 shows the 
explanation that was displayed on the second screen for a respondent who chose patient group A in 
practice question 1. Respondents were asked on the second screen whether they still wished to treat 
that group, and started the next question if they did not change their mind, or were shown the question 
again from the first screen if they did change their mind. The same format was used if the respondent 
chose patient group B. Respondents were allowed up to 7 attempts at each practice question before 
moving on automatically to the next question. 
 
After the 2 practice questions, respondents self-completed 10 DCE questions, 9 questions on attitudes, 
and 17 questions covering EQ-5D, socio-demographics, understanding and what they thought of the 
survey. In each DCE question, one or more of the elements presented in the scenario varied. Normal life 
expectancy and normal HRQoL did not vary for individual participants.  
 
Attitudinal questions were included to determine respondents’ general views on BOI, TI and EOL. This 
enables further interpretation of the results of the practice questions and DCE analysis, as these should 
be in accordance with the results of the attitudinal questions that remove the complexities and 
intricacies of the DCE questions. The attitudinal questions were selected and worded with input from 
the DH. The questions were worded as simply as possible to try and ensure that they were not 
misunderstood, but this means that they involved a simplification of BOI, TI and EOL.
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Figure 3: Practice Question 1 when normal life expectancy=20, first screen 
Both groups of patients have a medical condition, and this affects their health and how long they live 
 
Patient group A 
Without treatment 
• will live for 10 years from today  
• with 50% health  
 
With treatment 
• will live for 11 years from today  
• with 60% health  
 
Patient group B  
Without treatment 
• will live for 10 years from today  
• with 50% health  
 
With treatment 
• will live for 12 years from today  
• with 70% health  
If these patients did not have a medical condition 
they would live in 100% health for 20 years (N) from today  
 
 
 
 
 
 
 
 
 
 
 
Only 1 patient group can be treated, the other patient group will live for the rest of their life without 
treatment 
Which patient group do you think the NHS should treat? 
Please make sure you consider in your answer: 
• the life of each patient group without treatment 
• the life of each patient group with treatment 
• the life of each patient group if they did not have a medical condition 
 
There are the same number of patients in each patient group. 
 
Remember that you can treat only 1 patient group. 
 
The patient group you do not treat will live the life without treatment. 
 
Patient group B 
              □ 
Patient group A 
              □ 
Without treatment Treatment gain No condition 
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 Figure 4: Practice Question 1 when normal life expectancy=20, second screen when respondent 
chose to treat patient group A 
Both groups of patients have a medical condition, and this affects their health and how long they 
live 
 
Patient group A 
Without treatment 
• will live for 10 years from today 
• with 50% health 
 
With treatment 
• will live for 11 years from today 
• with 60% health 
 
Patient group B  
Without treatment 
• will live for 10 years from today 
• with 50% health 
 
With treatment 
• will live for 12 years from today 
• with 70% health 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.3 Analysis of data 
 
2.3.1 Model type 
The DCE data was modelled based on a random utility (RUT) framework.[Luce, 1959; McFadden, 
1974] Within the RUT framework, utility 𝑈𝑈𝑖𝑖𝑖𝑖  for an individual i is assumed to be a function of an 
explainable utility component 𝑉𝑉𝑖𝑖𝑖𝑖 and a random component 𝜀𝜀𝑖𝑖𝑖𝑖: 
     𝑈𝑈𝑖𝑖𝑖𝑖 = 𝑉𝑉𝑖𝑖𝑖𝑖 + 𝜀𝜀𝑖𝑖𝑖𝑖      (1) 
 
where j represents the alternatives individuals have within a choice set. The alternative chosen by 
the individual is assumed to confer greater utility than the other alternative. Choices are based on a 
The impact on how long the patients live and their health from having the medical condition was the 
same for both patient groups. 
 
You chose that the NHS should treat patient group A. 
 
These patients will live for 11 years from today with 60% health.  
 
Patient group B will not be treated. These patients will live for 10 years from today with 50% health. 
 
You have chosen the treatment that gives the smallest treatment gain. 
 
Do you still think that the NHS should treat patient group A? 
Yes 
  □ 
 No 
  □ 
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 set of attributes captured in Vij. Other influencing factors that are not observed are captured by the 
random component. DCE data provide the alternatives that individuals have chosen, in this case 
whether respondents were willing to treat patient group A or patient group B and these are 
modelled using the conditional logistic model which models the probability that individual i chooses 
profile j, so that the probability of an individual choosing to treat patient group A over patient group 
B (PA) is given by: 
 
exp( )
exp( ) exp( )
A
A
A B
VP
V V
=
+
  (2) 
 
where VA and VB represent the utility that the person derives from choosing to treat patient group A 
and B, respectively. V, is modelled as a function of a vector of attributes z.  
 
      𝑉𝑉 = 𝑓𝑓 (𝐳𝐳)      (3) 
 
The vector z contains the variables from the DCE. Participants in the survey used the information in 
the questionnaire text, the graph or both (Figure 3) to make decisions about which profile was 
preferred. This may have been based on absolute values, where the concern is the difference 
between health before and after treatment or relative differences that are standardised in some 
way. Variables are described first in terms of absolute values and second in terms of relative 
variables. 
 
2.3.2 Alternative absolute variables for the econometric models 
 
1) Life expectancy and HRQoL before (H, E) and after treatment (H+Q, E+S)  
The simplest model that is closest to the way data are presented to respondents is in the form of life 
expectancy and HRQoL before and after treatment. Life expectancy and HRQoL before treatment are 
E and H respectively and are presented in the text describing the alternatives. Life expectancy and 
HRQoL after treatment are these variables summed with the changes in life expectancy and HRQoL 
of S and Q respectively. E and H are expected to be negative and E+S and H+Q are expected to be 
positive if respondents give greater weight to those in poorer health and those getting larger gains 
respectively. 
 
2) QALY gains from treatment and burden of illness from condition (BOI)  
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 This model is more relevant from a policy perspective, since one QALY gain is the standard 
numeraire used in cost effectiveness assessments of new technologies by NICE,[2013] SMC,[2013] 
and AWMSG.[2012] QALY squared was included to capture the effect of TI. BOI is defined as it is in 
Figure 2 as being composed of QALYs lost from a condition compared to a normal life expectancy 
and 100% HRQoL. It is composed of losses from premature mortality and morbidity. All the 
coefficients on these terms are expected to be positive if respondents give greater weight to QALY 
gains, TI (QALY squared term) and BOI. 
 
A related model examines splitting BOI into losses from premature mortality (BOISU) and morbidity 
(BOIQL). Coefficients on these terms are also expected to be positive. 
 
3) QALY gains from treatment and end of Life (EOL) 
This model examines the role of life expectancy before treatment or pre-treatment survival in 
respondent choices. Life expectancy (E) is included separately as a continuous variable in one model 
or as a dummy variable representing EOL (i.e. E of 2 years or less with survival gains of 3 months or 
more representing NICE criteria for end of life)[NICE, 2009] in another model. E is expected to be 
negative. EOL is expected to be positive if respondents give greater weight to shorter life expectancy 
with current treatment but where new treatment offers gains of 3 months or more. 
 
It should be noted that BOI and EOL are not entered into the same model given the conceptual 
overlap between the two. This is reflected in the way E is a key driver in BOI (BOISU and BOIQL).  
 
It was also decided for completeness to run a model with QALY and E and H rather than BOI. E and H 
are expected to be negative if respondents give greater weight to those in poorer health with 
current treatment. 
 
2.3.3 Relative or standardised models 
Respondents’ choices may be driven by the relative sizes of the QALY gain or BOI, rather than their 
absolute value. There is some support for this in the literature, such as the notion of proportional 
shortfall described by Johannesson[2001] and Stolk et al.[2005] where BOI is expressed as a 
proportion of the loss in QALYs from the condition divided by the QALY profile expected without the 
condition. The proportional shortfall idea has been incorporated into health care assessment in the 
Netherlands and it was decided to examine it here. The idea of standardising was extended to QALY 
gains and BOI used in the current research.  
30 
 The original small scale study by Stolk and colleagues takes into account from the moment of 
intervention, expected QALYs without treatment relative to expected QALYs without the condition; 
i.e. if there was a ‘wonder pill’ that could restore the patient to full health.[Stolk et al, 2005] This 
would equate to baseline health i.e. health and life expectancy without treatment (area F in Figure 
2) relative to overall health (1*N) in the models estimated here. Stolk et al.[2005] operationalize 
proportional shortfall as 1-(expected QALYs without treatment /expected QALYs without the 
condition) so that higher values represent conditions with higher burden. In the models estimated 
here, this is equivalent to 1 minus BOI divided by N; i.e. 1-BOI/N = (N-F)/N = 1-F/N. It is important to 
bear in mind that the current study did not have a wonder pill profile. Results could be affected by 
the scale of life expectancy that respondents saw (5, 20, 40 and 80 years) and standardising the 
different questionnaire variants enables comparisons. QALYs and terms for survival may be 
influenced by N, and so models have been examined where they are standardised in the same way 
by dividing by N. All models where variables are divided by N are referred to as standardised for 
consistency. 
 
The variables used in the models presented in this report and how they are derived are summarised 
in Table 3. 
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 Table 3: Variables used in the models 
Variable Description Text  
(Figure 3) Derived 
H HRQoL with condition and without treatment H - 
E Life expectancy with condition and without 
treatment E - 
HQ HRQoL with condition and with treatment H+Q  
ES Life expectancy with condition and with 
treatment E+S  
Q HRQoL gains from treatment Q - 
S Survival gains from treatment S - 
    
stdH Standardised H - H/100 
stdE Standardised E - E/N 
stdHQ Standardised HQ - (H+Q)/100 
stdES Standardised ES - (E+S)/N 
N Normal life expectancy in profile N - 
EOL End of Life  - EOL=1 if E≤2 and S≥3 months 
    
QALY Expected quality adjusted life year gains from 
treatment [C + D] (E*Q/100)+( S((H+Q)/100))   
BOI Expected quality adjusted life year loss from 
condition without treatment 
[A+B+C+D]= 
[N - F] N – (H/100*E) 
    
stdQALY Standardised QALY [C + D]/N {(E*Q/100)+(S((H+Q)/100))}/N   
stdBOI Standardised BOI/Proportional shortfall 1-F/N= 
[N - F]/N {N – (H/100*E)}/N 
    
BOIQL Expected quality adjusted life year loss in HRQoL 
from condition without treatment [B+D] E -((H/100)*E) 
BOISU Expected quality adjusted life year loss in survival 
from condition without treatment [A+C] N-E 
    
stdBOIQL Standardised BOIQL [B+D]/N {E -((H/100)*E)}/N 
stdBOISU Standardised BOISU [A+C]/N {N-E}/N 
 
2.3.4 Model specification 
The function can take many different forms. The survey was designed to estimate an additive model 
where each attribute is entered as an independent main effect.   
𝑉𝑉 = 𝛽𝛽𝑖𝑖𝑖𝑖𝐳𝐳𝑖𝑖𝑖𝑖  + 𝛾𝛾𝑖𝑖𝑖𝑖 𝐳𝐳𝑖𝑖𝑖𝑖2  + 𝜀𝜀        (4) 
 
where V represents utility, z represents a vector containing the variables described in the section 
above and 𝑧𝑧2 represents squared terms. β captures the linear relationship between z and utility 
while 𝛾𝛾 captures non-linear effects. This model specification was chosen, as opposed to the 
specification used by Lancsar et al.,[2011] to keep the model as simple and transparent as possible. 
An additive model based on equation 4, for the simple QALY, BOI model is given by: 
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    V = 𝛽𝛽1𝑄𝑄𝑄𝑄𝑄𝑄𝑄𝑄+𝛽𝛽2𝑄𝑄𝑄𝑄𝑄𝑄𝑄𝑄2+𝛽𝛽3𝐵𝐵𝐵𝐵𝐵𝐵         (5) 
 
The marginal rate of substitution (MRS) of BOI for QALYs is generated from equation (5) using the 
ratio of the marginal utility of BOI to the marginal utility of a QALY: 
 
𝑀𝑀𝑀𝑀𝑀𝑀 = − 𝛽𝛽3
𝛽𝛽1+2𝛽𝛽2𝑄𝑄𝑄𝑄𝑄𝑄𝑄𝑄
                                                                                      (6) 
 
A value of 1 QALY is used in equation (6) to generate the marginal rate of substitution for illustrative 
purposes. The marginal rate of substitution of EOL for QALYs is generated using the equivalent 
regression containing terms for QALY, QALY squared and EOL.  
   
2.3.5 Model performance 
Performance of all regression models was assessed using the log-likelihood, Rho-squared, Akaike 
Information Criterion (AIC)[Akaike, 1973] and the Schwarz Bayesian Information Criterion 
(BIC).[Schwarz, 1978] Models are preferred with larger log likelihood and larger Rho-squared. 
Models with lower AIC and BIC are preferred, but the penalty for the inclusion of additional variables 
in BIC is larger than in AIC, meaning that BIC tends to favour models with fewer variables than AIC. 
Collinearity was also assessed using the variance inflation factor (VIF), with values greater than 10 as 
evidence of collinearity.  
2.3.6 Robustness of results 
Robustness of results was assessed by excluding responses from individuals who may have not 
understood or engaged with the survey. A number of exclusion criteria were examined:  
- respondents who reported that they found the survey quite or very difficult  
- respondents who took less than 5 minutes or more than 60 minutes to complete the survey  
- respondents who selected to treat the same condition for all 10 questions (this may indicate 
respondents were selecting either all left or right sides of the screen) 
- respondents who chose a profile that had a larger number of total lifetime QALYs after 
treatment, but smaller QALY gain from treatment and lower BOI before treatment than the 
other profile. These respondents were excluded on the grounds that they probably 
misunderstood the task as they chose the profile they thought was best or that they wanted 
to live in, not the profile with the patients who were most deserving of treatment. 
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 - the first survey question from all respondents because it was likely to be the least reliable. 
Questions were allocated to respondents in a random order and therefore exclusion of the 
first question should have no systematic impact on results. 
The regression models were re-run with each of these exclusions to examine the impact of these 
exclusions on the sign, significance and size of the coefficients. Finally, the consistency of the 
regression results with responses to the attitude questions were examined by re-estimating models 
for those who expressed attitudes favourable or unfavourable to BOI, TI and EOL. 
3 RESULTS  
3.1 Sample 
3,669 respondents completed this online survey, providing a response rate of 55% of people who 
accessed this survey and another survey conducted simultaneously and analysed elsewhere. Sample 
sizes across the 4 normal life expectancy groups ranged from 760 to 1,022. Response rates were 
lower than in the fourth preparatory study, but this may be expected due to the more restrictive 
sampling undertaken in the main study which was required to achieve a target quota of respondents 
aged over 65 and large target numbers of respondents who are harder to obtain responses from, 
such as 25-44 year old males. All respondents completed every question. No respondents were 
excluded from the main analysis. 
 
Characteristics of the samples are compared to the general population in England in Table 4. In 
comparison to the general population of England, those who completed the survey had a similar age 
distribution but with a higher proportion of females, unemployed individuals, long-term sick and 
retired, and a lower proportion of individuals who were employed or self-employed. The sample also 
had a lower EQ-5D score than the general population of England, indicating poorer health. Although 
66.9% of individuals stated their health in general was good or very good, 37% stated that they were 
limited by a long term health condition or disability and 33.6% stated they had experienced serious 
illness in themselves. A large proportion of the sample, 48.2%, had a degree or equivalent 
professional qualification.  
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 Table 4: Socio-demographic characteristics 
 All respondents England * 
N 3,669  
Mean age (s.d.) 46.5 (16.6) NA 
Age distribution (years)   
       18-40 39.9% 41.6% 
       41-65 42.1% 39.1% 
       Over 65 18.0% 19.3% 
Female 54.3% 51.3% 
Married/Partner 62.4% NA 
Employed or self-employed 47.3% 60.9% 
Unemployed 6.2% 3.4% 
Long-term sick 6.4% 5.3% 
Full-time student 7.2% 7.3% 
Retired 23.8% 13.5% 
Secondary school is highest level of education 21.6%  
Degree or equivalent professional qualification 48.2%  
Health in general is very good or good 66.9%  
Limited by long term health condition or disability 37.0%  
EQ-5D score, mean (s.d.) 0.78 (0.26) 0.86 (0.23)† 
Experienced serious illness in yourself 33.6%  
Experienced serious illness in family 74.5%  
Experienced serious illness in caring for others 33.5%  
Notes: * Statistics for England in the Census 2001. Questions used in this study and the census are not identical. The census 
includes persons aged 16 and above whereas this study only surveys persons aged 18 and above. Age distribution is here 
reported as the percentage of all adults aged 18 and over. 
† Interviews conducted in the Measurement and Valuation of Health (MVH) study (Kind et al, 1999). Ara and Brazier (2011) 
report a mean EQ-5D score of 0.87 generated using the Health Survey for England. NA=Not available 
 
The median completion times from consent to the end of the survey was 21 minutes (IQR 17-27 
minutes) with the majority of respondents (≈ 80%) spending less than 30 minutes on the survey, but 
for a small proportion (≈ 5%) of respondents the entire survey took over an hour. Most (>80%) spent 
less than 10 minutes on the introduction video and practice questions, suggesting the respondent 
watched the video and then considered the practice questions. However, some respondents had 
long times (up to 1 hour) that suggest they may have left the survey idle in this time and therefore 
there are doubts as to whether these respondents watched the video.  
 
3.2 Respondent views of the survey 
The majority of respondents, 77.7%, reported that the DCE questions were either very easy (36.1%) 
or fairly easy (41.6%) to understand, varying from 76.2% to 79.5% across the different life 
expectancies. The majority of respondents, 77.7%, also reported that the attitudinal questions were 
either very easy (36.8%) or fairly easy to understand (40.9%), varying from 76.2% to 80% across the 
life expectancies. 
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3.3 Practice questions 
In practice question 1, respondents overwhelmingly chose to treat the group with the highest 
treatment gain, patient group B, and this is consistent across the different normal life expectancy 
variants, varying from 90.7% to 92.5% (Table 5). In practice question 2, patient group A is the group 
with the higher BOI, but there is limited evidence that respondents prefer to treat this patient group 
with 46.8%, 54.3%, 52.3% and 50.7% across the four versions choosing this group (Table 5). 
 
Overall 4.9% and 6.9% of respondents changed their selection following the first explanation in 
practice questions 1 and 2 respectively and when they were faced again with the original question 
62.7% and 73.0% respectively made a different choice. Out of those, 81.2% chose to treat the group 
with the highest treatment gain in practice question 1, and for practice question 2, 76.0% chose to 
treat the group with the highest BOI. These results suggest that the explanations did clarify the 
profiles for some respondents and these respondents altered their choices.  
 
Table 5: Responses to practice questions 
Practice 
Question 
Normal life 
expectancy 
Practice question  
First response 
Practice question  
Second response 
Practice question  
Final response 
  n A B n A B n A B 
1 5 1,022 7.7% 92.3% 42 26.2% 73.8% 1,022 6.8% 93.2% 
 20 760 8.7% 91.3% 28 14.3% 85.7% 760 7.1% 92.9% 
 40 889 9.3% 90.7% 54 22.2% 77.8% 889 7.8% 92.2% 
 80 998 7.5% 92.5% 55 23.6% 76.4% 998 6.5% 93.5% 
2 5 1,022 41.9% 58.1% 77 68.8% 31.2% 1,022 46.8% 53.2% 
 20 760 50.4% 49.6% 45 75.6% 24.4% 760 54.3% 45.7% 
 40 889 48.5% 51.5% 60 65.0% 35.0% 889 52.3% 47.7% 
 80 998 47.5% 52.5% 70 61.4% 38.6% 998 50.7% 49.3% 
Notes: Respondents who stated after the explanation of their choice that they did not still want to treat the same group 
were asked the question again, and this process was repeated allowing respondents up to 7 attempts in total before 
moving on to the next question. 
 
3.4 Regression results 
3.4.1 HRQoL and life expectancy before and after treatment 
Table 6 summarises the results based on HRQoL before (H) and after (HQ) treatment and life 
expectancy before (E) and after (ES) treatment in absolute and standardised terms. As expected, H 
and E are negative while HQ and ES are positive across the questionnaire variants indicating that 
respondents were less likely to choose profiles with high levels of HRQoL and life expectancy before 
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 treatment, and more likely to choose profiles with high levels of HRQoL and life expectancy after 
treatment.  
 
Table 6: HRQoL and life expectancy before and after treatment 
Variables All 5yrs 20yrs 40yrs 80yrs 
H -0.033128*** -0.037765*** -0.035411*** -0.036326*** -0.035009*** 
 (0.000) (0.000) (0.000) (0.000) (0.000) 
E -0.087855*** -1.043415*** -0.196465*** -0.170115*** -0.035783*** 
 (0.000) (0.000) (0.000) (0.000) (0.000) 
HQ 0.048005*** 0.053244*** 0.051889*** 0.048480*** 0.051085*** 
 (0.000) (0.000) (0.000) (0.000) (0.000) 
ES 0.095849*** 1.178916*** 0.241505*** 0.172891*** 0.044745*** 
 (0.000) (0.000) (0.000) (0.000) (0.000) 
Log likelihood -20433 -5173 -3980 -4980 -5083 
Rho-squared 0.197 0.270 0.244 0.192 0.265 
AIC 40875 10354 7969 9967 10174 
BIC 40912 10385 7999 9999 10205 
Mean VIF 2.12 2.18 1.88 6.07 1.79 
      
stdH -3.584132*** -3.776524*** -3.541122*** -3.632648*** -3.500938*** 
 (0.000) (0.000) (0.000) (0.000) (0.000) 
stdE -4.544852*** -5.217076*** -3.929310*** -6.804589*** -2.862620*** 
 (0.000) (0.000) (0.000) (0.000) (0.000) 
stdHQ 5.088076*** 5.324445*** 5.188886*** 4.847972*** 5.108451*** 
 (0.000) (0.000) (0.000) (0.000) (0.000) 
stdES 5.047739*** 5.894578*** 4.830097*** 6.915660*** 3.579621*** 
 (0.000) (0.000) (0.000) (0.000) (0.000) 
Log likelihood -19327 -5173 -3980 -4980 -5083 
Rho-squared 0.240 0.270 0.244 0.192 0.265 
AIC 38662 10354 7969 9967 10174 
BIC 38699 10385 7999 9999 10205 
Mean VIF 2.12 2.18 1.88 6.07 1.79 
Observations 73,380 20,440 15,200 17,780 19,960 
pval in parentheses; *** p<0.01, ** p<0.05, * p<0.1; H and E HRQoL and life expectancy before treatment; HQ and ES 
HRQoL and life expectancy after treatment  
 
The coefficients on HRQoL terms are stable across the questionnaire variants while life expectancy 
terms vary with normal life expectancy. The absolute size of the coefficients on life expectancy 
without treatment (E) and life expectancy with treatment (ES) decreases as normal life expectancy 
increases, with the largest difference between 5 and 20 years. Standardisation reduces the 
differences in the life expectancy terms but does not remove them completely and there is an 
anomaly at 40 years. These results suggest that although normal life expectancy (N) did not vary for 
individual respondents, it may have influenced the results.  
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 3.4.2 QALY gains and BOI 
Table 7 summarises the results based on QALY gains and BOI (QALY loss). As expected QALY gains 
are positive; BOI is small and mainly positive, indicating that respondents preferred profiles with 
higher QALY gains and also higher BOI. QALY squared is negative, indicating that QALY gains were 
preferred at a decreasing rate. BOI squared was tested but did not improve the models and although 
it was statistically significant in some models, BOI was no longer statistically significant, hence the 
squared term has not been included here. The marginal rate of substitution of 1 unit of BOI is -0.027 
QALYs using the 80 year variant and the regressions using non-standardised variables.  
 
Table 7: QALY and BOI  
Variables All 5yrs 20yrs 40yrs 80yrs 
QALY 0.275717*** 3.641225*** 0.750890*** 0.403637*** 0.171109*** 
 (0.000) (0.000) (0.000) (0.000) (0.000) 
QALY_sq -0.003827*** -0.708627*** -0.037264*** -0.014023*** -0.002050*** 
 (0.000) (0.000) (0.000) (0.000) (0.000) 
BOI 0.017239*** 0.119966*** -0.000024 0.038750*** 0.004505** 
 (0.000) (0.000) (0.998) (0.000) (0.015) 
Log likelihood -21775 -5160 -4043 -5246 -5416 
Rho-squared 0.144 0.272 0.232 0.149 0.217 
AIC 43555 10326 8093 10498 10838 
BIC 43582 10350 8116 10521 10861 
Mean VIF 5.35 6.92 4.77 5.39 7.42 
stdQALY 14.9943*** 18.20613*** 15.01781*** 16.14547*** 13.68874*** 
 (0.000) (0.000) (0.000) (0.000) (0.000) 
stdQALY_sq -14.80278*** -17.71567*** -14.90545*** -22.4361*** -13.11786*** 
 (0.000) (0.000) (0.000) (0.000) (0.000) 
stdBOI 0.758085*** 0.599828*** -0.000477 1.549989*** 0.360379** 
 (0.000) (0.000) (0.998) (0.000) (0.015) 
Log likelihood -20004 -5160 -4043 -5246 -5416 
Rho –squared 0.213 0.272 0.232 0.149 0.217 
AIC 40015 10326 8093 10498 10838 
BIC 40042 10350 8116 10521 10861 
Mean VIF 5.70 6.92 4.77 5.39 7.42 
Observations 73,380 20,440 15,200 17,780 19,960 
pval in parentheses; *** p<0.01, ** p<0.05, * p<0.1; QALY – QALY gains from new treatment; QALY_sq – QALY squared; 
BOI – QALY loss from condition with current treatment 
 
The coefficient size of QALY gains and QALY squared falls as normal life expectancy increases with 
the largest difference between 5 and 20 years (Table 7). The coefficient size of BOI also falls between 
5 and 80 years, but not monotonically. Standardising the QALY coefficients by dividing QALY gain by 
N substantially reduces the differences between the four questionnaire variants. By contrast, 
standardising BOI does not reduce the differences between the coefficients and so the results would 
not seem to support the proportional shortfall model.  
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 Table 8 summarises the results where BOI is split between premature mortality and morbidity. QALY 
and QALY squared are positive and negative respectively as before and similar in magnitude to the 
previous models. In the pooled data set, the BOI from HRQoL loss (BOIQL) is negative while burden 
from life years (BOISU) lost is positive. This indicates that respondents were more likely to choose 
profiles with higher burden from life years but lower burden in HRQoL. These terms are not 
consistent in direction between the four questionnaire variants, though these coefficients are not 
significant across all the questionnaires. 
 
Standardisation substantially reduces differences in the coefficients on the QALY terms between the 
four variants, but large differences remain in the BOIQL and BOISU coefficients. 
 
Table 8: QALY and split BOI  
Variables All 5yrs 20yrs 40yrs 80yrs 
QALY 0.309185*** 3.626376*** 0.783542*** 0.434236*** 0.191784*** 
 (0.000) (0.000) (0.000) (0.000) (0.000) 
QALY_sq -0.004325*** -0.697661*** -0.038518*** -0.013868*** -0.002361*** 
 (0.000) (0.000) (0.000) (0.000) (0.000) 
BOIQL -0.027300*** 0.000408 -0.070746*** -0.011632** -0.019680*** 
 (0.000) (0.992) (0.000) (0.024) (0.000) 
BOISU 0.009186*** 0.149561*** -0.002667 0.032543*** -0.000020 
 (0.000) (0.000) (0.825) (0.000) (0.992) 
Log likelihood -21489 -5148 -4013 -5138 -5346 
Rho-squared 0.155 0.273 0.238 0.166 0.227 
AIC 42987 10303 8034 10284 10700 
BIC 43024 10335 8064 10315 10731 
Mean VIF 4.85 6.95 5.26 6.18 8.04 
stdQALY 16.026469*** 18.131878*** 15.670843*** 17.369445*** 15.342754*** 
 (0.000) (0.000) (0.000) (0.000) (0.000) 
stdQALY_sq -15.843892*** -17.441529*** -15.407104*** -22.189126*** -15.107985*** 
 (0.000) (0.000) (0.000) (0.000) (0.000) 
stdBOIQL -0.879914*** 0.002041 -1.414921*** -0.465295** -1.574378*** 
 (0.000) (0.992) (0.000) (0.024) (0.000) 
stdBOISU 0.651972*** 0.747806*** -0.053345 1.301718*** -0.001593 
 (0.000) (0.000) (0.825) (0.000) (0.992) 
Log likelihood -19753 -5148 -4013 -5138 -5346 
Rho-squared 0.223 0.273 0.238 0.166 0.227 
AIC 39514 10303 8034 10284 10700 
BIC 39550 10335 8064 10315 10731 
Mean VIF 6.25 6.95 5.26 6.18 8.04 
Observations 73,380 20,440 15,200 17,780 19,960 
pval in parentheses; *** p<0.01, ** p<0.05, * p<0.1; QALY – QALY gains from new treatment; QALY_sq – QALY squared; 
BOIQL – QALY loss due to poor HRQoL; BOISU – QALY loss due to shorter life expectancy  
 
3.4.3 QALY gains and life expectancy before treatment or end of life  
As before, the QALY coefficient is positive and the QALY squared coefficient is negative and both 
effects are similar to previous models (Table 9). Survival before treatment (E) is negative and 
statistically significant across the models and improves their overall performance. The coefficients 
39 
 on survival before treatment decline with increasing normal life expectancy. In regressions involving 
EOL with survival gains of 3 or more months rather than E, EOL is positive indicating respondents 
gave greater weight to shorter life expectancy before treatment when survival gains were greater 
than 3 months. However, as would be expected due to the loss of information when E is converted 
to a dummy variable, these models perform worse than equivalent models including E. The 
coefficients on EOL also decline with normal life expectancy except for the 40 year variant. 
Standardisation stabilises the coefficients across the questionnaire variants apart from the 40 year 
variant. The marginal rate of substitution of EOL is -1.84 QALYs using the 80 year variant and 
regression using non-standardised variables. 
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 Table 9: QALY gains and life expectancy before treatment/ end of life 
Variables All 5yrs 20yrs 40yrs 80yrs 
QALY 0.307033*** 3.626240*** 0.787416*** 0.437654*** 0.189601*** 
 (0.000) (0.000) (0.000) (0.000) (0.000) 
QALY_sq -0.004302*** -0.697631*** -0.038544*** -0.014124*** -0.002337*** 
 (0.000) (0.000) (0.000) (0.000) (0.000) 
E -0.024580*** -0.149347*** -0.043401*** -0.039460*** -0.010979*** 
 (0.000) (0.000) (0.000) (0.000) (0.000) 
Log likelihood -21545 -5148 -4024 -5140 -5371 
Rho-squared 0.153 0.273 0.236 0.166 0.224 
AIC 43096 10301 8054 10287 10747 
BIC 43123 10325 8077 10310 10771 
Mean VIF 5.99 6.93 4.81 5.37 7.99 
stdQALY 16.091462*** 18.13120*** 15.74831*** 17.50618*** 15.16804*** 
 (0.000) (0.000) (0.000) (0.000) (0.000) 
stdQALY_sq -15.94931*** -17.44077*** -15.41745*** -22.5982*** -14.9555*** 
 (0.000) (0.000) (0.000) (0.000) (0.000) 
stdE -1.162729*** -0.746736*** -0.868016*** -1.578411*** -0.878320*** 
 (0.000) (0.000) (0.000) (0.000) (0.000) 
Log likelihood -19784 -5148 -4024 -5140 -5371 
Rho-squared 0.222 0.273 0.236 0.166 0.224 
AIC 39575 10301 8054 10287 10747 
BIC 39602 10325 8077 10310 10771 
Mean VIF 5.83 6.93 4.81 5.37 7.99 
QALY 0.281260*** 3.229699*** 0.761621*** 0.400385*** 0.175159*** 
 (0.000) (0.000) (0.000) (0.000) (0.000) 
QALY_sq -0.003906*** -0.602180*** -0.036789*** -0.013910*** -0.002117*** 
 (0.000) (0.000) (0.000) (0.000) (0.000) 
EOL 0.609437*** 0.606509*** 0.375107*** 0.576401*** 0.314355*** 
 (0.000) (0.000) (0.000) (0.000) (0.000) 
Log likelihood -21411 -5103 -4008 -5203 -5395 
Rho-squared 0.158 0.280 0.239 0.156 0.220 
AIC 42829 10213 8022 10411 10797 
BIC 42857 10236 8045 10435 10820 
Mean VIF 5.24 7.78 4.72 5.26 7.44 
stdQALY 14.748108*** 16.148494*** 15.232415*** 16.015386*** 14.012740*** 
 (0.000) (0.000) (0.000) (0.000) (0.000) 
stdQALY_sq -14.409639*** -15.054491*** -14.715728*** -22.255325*** -13.549861*** 
 (0.000) (0.000) (0.000) (0.000) (0.000) 
EOL 0.487499*** 0.606509*** 0.375107*** 0.576401*** 0.314355*** 
 (0.000) (0.000) (0.000) (0.000) (0.000) 
Log likelihood -19806 -5103 -4008 -5203 -5395 
Rho-squared 0.221 0.280 0.239 0.156 0.220 
AIC 39619 10213 8022 10411 10797 
BIC 39646 10236 8045 10435 10820 
Mean VIF 5.54 7.78 4.72 5.26 7.44 
Observations 73,380 20,440 15,200 17,780 19,960 
pval in parentheses; *** p<0.01, ** p<0.05, * p<0.1; QALY – QALY gains from new treatment; QALY_sq – QALY squared 
E –life expectancy before treatment; EOL – life expectancy before treatment ≤2 years and with survival gains≥ 3 months. 
 
 
3.4.4 QALY gains and HRQoL and life expectancy before treatment 
Life expectancy before treatment (E) is negative, statistically significant and a similar magnitude to 
those reported in models with only E (Table 10). Standardised HRQoL before treatment (stdH) is 
positive and statistically significant before treatment. E and H both appear in the QALY so the 
coefficients on their own cannot be assessed. Further assessment indicates that the effect of E is 
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 negative within the range of likely levels of E (i.e. less than 100 years) while H is positive. This 
indicates that respondents were more likely to choose profiles with lower life expectancy but with 
higher HRQoL which supports the split BOI finding for burden from HRQoL but is in contrast to the 
results where there are no QALY terms (Table 6). Standardisation minimises differences across the 
questionnaire variants apart from the 40 year variant. 
 
Table 10: QALY gains with life expectancy and HRQoL before treatment  
Variables All 5yrs 20yrs 40yrs 80yrs 
      
QALY 0.295534*** 3.590566*** 0.765465*** 0.431436*** 0.184972*** 
 (0.000) (0.000) (0.000) (0.000) (0.000) 
QALY_sq -0.004176*** -0.690254*** -0.038048*** -0.013868*** -0.002303*** 
 (0.000) (0.000) (0.000) (0.000) (0.000) 
E -0.023122*** -0.146742*** -0.041931*** -0.038626*** -0.010430*** 
 (0.000) (0.000) (0.000) (0.000) (0.000) 
stdH 0.792473*** 0.128931 0.775565*** 0.251165*** 0.639825*** 
 (0.000) (0.135) (0.000) (0.003) (0.000) 
Log likelihood -21348 -5147 -3987 -5136 -5341 
Rho-squared 0.161 0.273 0.243 0.167 0.228 
AIC 42705 10301 7982 10280 10689 
BIC 42742 10322 8012 10311 10721 
Mean VIF 4.75 5.47 3.86 4.34 6.39 
      
stdQALY 15.70341*** 17.95283*** 15.3093*** 17.25744*** 14.79776*** 
 (0.000) (0.000) (0.000) (0.000) (0.000) 
stdQALY_sq -15.61605*** -17.25636*** -15.21917*** -22.18838*** -14.74235*** 
 (0.000) (0.000) (0.000) (0.000) (0.000) 
stdE -1.112958*** -0.733708*** -0.838610*** -1.545033*** -0.834435*** 
 (0.000) (0.000) (0.000) (0.000) (0.000) 
stdH 0.478945*** 0.128931 0.775565*** 0.251165*** 0.639825*** 
 (0.000) (0.135) (0.000) (0.003) (0.000) 
Log likelihood -19721 -5147 -3987 -5136 -5341 
Rho-squared 0.225 0.273 0.243 0.167 0.228 
AIC 39450 10301 7982 10280 10689 
BIC 39487 10322 8012 10311 10721 
Mean VIF 4.62 5.47 3.86 4.34 6.39 
Observations 73,380 20,440 15,200 17,780 19,960 
pval in parentheses; *** p<0.01, ** p<0.05, * p<0.1; QALY – QALY gains from new treatment; QALY_sq – QALY squared; H 
and E – HRQoL and life expectancy before treatment 
Notes: stdH i.e. H/100 is used in the unstandardized QALY model to reflect the fact that H/100 is used to build the QALY. 
This has no effect on the direction of the coefficient; it just increases the magnitude by a factor of 100. 
 
 
3.4.5 Comparison of model performance 
The best fitting models based on the log-likelihood, rho-squared, BIC and AIC are the ones with 
simple terms for HRQoL and life expectancy before and after treatment models (H, H+Q, E, E+S). 
When comparing the QALY models, which are more relevant for policy, the best fitting models are 
those with HRQoL and life expectancy before treatment rather than BOI. Splitting BOI resulted in 
better performing models using all model performance criteria, yet the interpretation and suitability 
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 of the split variables is questionable. Standardisation improves the performance of models when 
results are pooled across the questionnaire variants, but makes no difference within variant as 
would be expected. Mean variance inflation factors (VIF) across all the models were less than 10 
indicating that there was no collinearity. Individual VIFs across the terms (not reported) show that 
the only terms with VIF factors higher than 5 were squared terms i.e. QALY squared which is 
expected. All other terms such as BOI and E had VIFs of approximately 1.  
 
3.4.6 Robustness of results 
There were concerns that respondents who did not understand or engage with the survey may have 
had an impact on results. First, the consequences were examined of excluding the following: 279 
individuals who reported they had difficulty understanding the DCE questions; 208 individuals who 
took less than 5 minutes or more than 60 minutes to complete the survey; and 23 individuals who 
chose the same option for all their DCE questions. These exclusions did not have consequences for 
the significance and direction of the QALY, BOI and EOL coefficients, though there were variations in 
magnitude for all of them. The impact of excluding the first question for each individual to test for 
learning effects was also examined, and no impact on the coefficients in terms of significance and 
direction was found but there were small changes in magnitude. 
 
Second, the consequences of excluding individuals from the analyses who arguably misunderstood 
the DCE task were examined. 1,442 respondents were excluded who chose a profile that had a larger 
number of total lifetime QALYs after treatment, but smaller QALY gain from treatment and lower 
BOI before treatment than the other profile. These respondents were excluded on the grounds that 
they misunderstood the task as they chose the profile they thought was best or that they wanted to 
live in, not the profile with the patients who were most deserving of treatment in terms of size of 
QALY gain and BOI. Some respondents did not answer a question that could be used to implement 
this exclusion criteria, and these 369 respondents remained in the analysis, though it is possible that 
some of these respondents may have also misunderstood the DCE task. Appendix 2, Table 1 provides 
summary characteristics of the sample of excluded respondents and the remaining sample of 2,247 
respondents. In comparison to the remaining sample, the sample of respondents who 
misunderstood the DCE task had a higher proportion of older respondents, respondents who were 
retired or long-term sick and whose highest level of education was secondary school, respondents in 
poorer health and respondents who found the DCE and attitudinal questions difficult. Appendix 2, 
Table 2 provides responses to the practice questions, demonstrating that in practice question 1, a 
larger proportion of respondents (91.4% in full sample compared to 94.0% for the sample excluding 
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 respondents who misunderstood the DCE task) chose to treat the group with the highest treatment 
gain. The results for practice question 2 are more striking, where the proportion of all respondents 
choosing to treat the patients with higher BOI was 50.8%, yet following the exclusion of respondents 
who misunderstood the DCE task the proportion choosing to treat the patients with higher BOI was 
63.5%. 
 
All regressions reported in section 3.4 were re-estimated excluding respondents who misunderstood 
the DCE task and are reported in Table 11 and Appendix 2. The results are consistent with the main 
results reported above for significance and direction of the QALY and EOL coefficients, though there 
were variations in magnitude for all of them. However, for BOI the coefficients are positive and 
significant at the 1% level and substantially larger in magnitude (Table 11). When BOI is split 
between premature mortality and morbidity the coefficients are always positive and are significant 
with the exception of the 80 year variant for BOI from HRQoL (Table 11). In addition the regressions 
estimated with QALY, QALY squared, life expectancy before treatment and standardised HRQoL 
before treatment have the expected significance and direction of coefficients where respondents 
are more likely to choose profiles with lower life expectancy and HRQoL before treatment. Overall 
these results suggest that there is a preference for BOI amongst respondents who seemed to have 
understood the DCE task.  
 
  
44 
 Table 11: QALY and BOI, and QALY and split BOI, excluding respondents who misunderstood the DCE 
task 
Variables All 5 years 20 years 40 years 80 years 
QALY 0.327731*** 4.296049*** 0.977076*** 0.534826*** 0.201342*** 
 (0.000) (0.000) (0.000) (0.000) (0.000) 
QALY_sq -0.004628*** -0.871767*** -0.050522*** -0.018881*** -0.002557*** 
 (0.000) (0.000) (0.000) (0.000) (0.000) 
BOI 0.071495*** 0.686080*** 0.284999*** 0.130007*** 0.035929*** 
 (0.000) (0.000) (0.000) (0.000) (0.000) 
Log likelihood -12923 -3239 -2086 -2698 -3330 
Rho-squared 0.170 0.326 0.282 0.217 0.247 
AIC 25851 6485 4178 5402 6666 
BIC 25878 6507 4199 5424 6688 
Mean VIF 5.61 6.99 5.04 5.23 7.42 
stdQALY 18.565652*** 21.480247*** 19.541523*** 21.393033*** 16.107366*** 
 (0.000) (0.000) (0.000) (0.000) (0.000) 
stdQALY_sq -19.338888*** -21.794173*** -20.208719*** -30.210193*** -16.363127*** 
 (0.000) (0.000) (0.000) (0.000) (0.000) 
stdBOI 3.946421*** 3.430399*** 5.699972*** 5.200264*** 2.874328*** 
 (0.000) (0.000) (0.000) (0.000) (0.000) 
Log likelihood -11470 -3239 -2086 -2698 -3330 
Rho-squared 0.264 0.326 0.282 0.217 0.247 
AIC 22945 6485 4178 5402 6666 
BIC 22972 6507 4199 5424 6688 
Mean VIF 5.79 6.99 5.04 5.23 7.42 
QALY 0.380000*** 4.396137*** 1.063459*** 0.601136*** 0.232766*** 
 (0.000) (0.000) (0.000) (0.000) (0.000) 
QALY_sq -0.005393*** -0.891345*** -0.054045*** -0.019291*** -0.003020*** 
 (0.000) (0.000) (0.000) (0.000) (0.000) 
BOIQL 0.019246*** 0.506098*** 0.143250*** 0.056376*** 0.005484 
 (0.000) (0.000) (0.000) (0.000) (0.126) 
BOISU 0.063979*** 0.735917*** 0.275993*** 0.123955*** 0.030458*** 
 (0.000) (0.000) (0.000) (0.000) (0.000) 
Log likelihood -12656 -3220 -2027 -2590 -3250 
Rho-squared 0.187 0.330 0.302 0.248 0.265 
AIC 25319 6448 4062 5188 6509 
BIC 25354 6478 4091 5216 6539 
Mean VIF 5.08 7.05 5.49 6.07 8.30 
stdQALY 20.632141*** 21.980684*** 21.269172*** 24.045446*** 18.621290*** 
 (0.000) (0.000) (0.000) (0.000) (0.000) 
stdQALY_sq -21.676245*** -22.283617*** -21.618083*** -30.866060*** -19.325591*** 
 (0.000) (0.000) (0.000) (0.000) (0.000) 
stdBOIQL 1.718467*** 2.530489*** 2.865009*** 2.255054*** 0.438691 
 (0.000) (0.000) (0.000) (0.000) (0.126) 
stdBOISU 3.847949*** 3.679584*** 5.519870*** 4.958199*** 2.436641*** 
 (0.000) (0.000) (0.000) (0.000) (0.000) 
      
Log likelihood -11190 -3220 -2027 -2590 -3250 
Rho-squared 0.282 0.330 0.302 0.248 0.265 
AIC 22389 6448 4062 5188 6509 
BIC 22424 6478 4091 5216 6539 
Mean VIF 6.42 7.05 5.49 6.07 8.30 
Observations 44,940 13,860 8,380 9,940 12,760 
pval in parentheses; *** p<0.01, ** p<0.05, * p<0.1; QALY – QALY gains from new treatment; QALY_sq – QALY squared; 
BOI – QALY loss from condition with current treatment; BOIQL – QALY loss due to poor HRQoL; BOISU – QALY loss due to 
shorter life expectancy 
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3.5 Attitudinal questions  
 
Results from the attitudinal questions are reported in Table 12. 
Table 12: Responses to the attitudinal questions 
 Normal life expectancy 5 20 40 80 All 
Question Response                                                                                             N 1022 760 889 998 3669 
 BOI      
1  The NHS should give priority to treating patients who are very ill 40.3% 41.7% 40.9% 40.2% 40.7% 
 The NHS should give the same priority to treating all patients 
who are ill, regardless of how ill they are 
59.7% 58.3% 59.1% 59.8% 59.3% 
2 The NHS should give priority to treating patients who are very ill 
and will die early because of their illness 
42.1% 41.6% 43.3% 42.8% 42.5% 
 The NHS should give the same priority to treating all patients 
who are ill, regardless of how ill they are or when they will die 
57.9% 58.4% 56.7% 57.2% 57.5% 
3 The NHS should always give priority to treating patients who are 
very ill and will die early because of their illness, even if they 
only get a small amount of benefit from treatment 
8.1% 9.9% 10.8% 9.6% 9.5% 
 The NHS should give priority to treating patients who are very ill 
and will die early because of their illness, but only if they get a 
large amount of benefit from treatment 
46.7% 44.5% 41.4% 44.7% 44.4% 
 The NHS should give the same priority to treating all patients, 
regardless of how ill they are or when they will die 
45.2% 45.7% 47.8% 45.7% 46.1% 
8 The NHS should give priority to treating patients who are very ill 
and will die early because of their illness 
9.3% 10.3% 12.8% 10.2% 10.6% 
 The NHS should give priority to treating patients who will get the 
largest amount of benefit from treatment 
47.2% 45.5% 43.0% 42.8% 44.6% 
 The NHS should give the same priority to treating all patients 43.5% 44.2% 44.2% 47.0% 44.8% 
 EOL      
4 The NHS should give priority to extending the life of patients 
who are expected to die soon, even if this is the natural end of 
their life 
5.7% 6.8% 7.3% 5.5% 6.3% 
 The NHS should give priority to patients expected to die soon, 
but only if it means they die before the natural end of their life 
38.6% 38.0% 37.7% 39.1% 38.4% 
 The NHS should give the same priority to treating all patients, 
regardless of how ill they are or when they will die 
55.7% 55.1% 55.0% 55.4% 55.3% 
5 The NHS should give priority to extending the life of patients 
who are expected to die soon, even if this means they live in 
very poor health 
3.1% 4.3% 4.2% 4.0% 3.9% 
 The NHS should give priority to extending the life of patients 
who are expected to die soon, but only if they would live in a 
reasonable level of health 
56.2% 57.0% 56.9% 55.7% 56.4% 
 The NHS should give the same priority to treating all patients, 
regardless of how ill they are or when they will die 
40.7% 38.7% 38.9% 40.3% 39.7% 
       
7 The NHS should give priority to extending the life of patients 
expected to die soon 
11.8% 12.0% 13.8% 10.7% 12.0% 
 The NHS should give priority to treating patients who will get the 
largest amount of benefit from treatment 
88.2% 88.0% 86.2% 89.3% 88.0% 
 Therapeutic Improvement      
6 The NHS should give priority to treatments that give a large 
amount of benefit to a small number of patients 
8.8% 8.2% 8.9% 6.8% 8.1% 
 The NHS should give priority to treatments that give a small 8.3% 11.3% 10.6% 8.3% 9.5% 
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  Normal life expectancy 5 20 40 80 All 
amount of benefit to a large number of patients 
 The NHS should consider the amount of benefit a treatment 
gives overall, rather than considering how it is shared out among 
different numbers of patients 
82.9% 80.5% 80.5% 84.9% 82.4% 
 Combined       
9 The NHS should give priority to treating patients who are very ill 
and will die early because of their illness 
12.8% 12.6% 14.4% 12.4% 13.1% 
 The NHS should give priority to treating patients who will get the 
largest amount of benefit from treatment 
52.2% 53.8% 52.8% 50.3% 52.1% 
 The NHS should give priority to treating patients who will live for 
a long time and be in good health after treatment 
35.0% 33.6% 32.8% 37.3% 34.8% 
 
 
3.5.1 Burden of illness (BOI) 
Just under half answered that the NHS should give priority to treating patients who are very ill (i.e. 
higher BOI) or those who are very ill and will die early (40.7% and 42.5% respectively) (Table 12, Q1 
and 2), rather than giving the same priority to all patients. Just 9.5% of respondents indicated that 
the NHS should give priority to treating patients who are very ill and will die early (i.e. higher BOI) if 
they only get a small amount of benefit from treatment compared to 44.4% of respondents who 
thought that the NHS should give priority to treating patients with a higher BOI but only if they get a 
large benefit from treatment, and 46.1% of respondents thought that the NHS should give the same 
priority to all patients (Q3). This implies that the value placed on BOI depends on the gain. 10.6% of 
respondents thought the NHS should give priority to patients with high BOI (i.e. very ill and will die 
early) compared to 44.6% of respondents who said that the NHS should give priority to patients with 
the highest treatment gain and 44.8% who thought the same priority should be given to all patients 
(Q8). Overall, this indicates that treatment gain was preferred over BOI but marginally more 
respondents preferred to give equal priority to all patients. 
 
Question 2 was used to assess whether the attitudes were consistent with the DCE results. The 
regression models were re-estimated using variables of QALY, QALY squared and BOI for subsamples 
generated using their responses to question 2. As would be expected, the regression estimated for 
the subsample who showed a preference for BOI, also had positive coefficients for BOI (Appendix 3 
Table 1) while those who did not show a preference for BOI had negative coefficients.  
 
3.5.2 End of life (EOL) 
Very few respondents indicated that the NHS should give priority to patients expected to die soon if 
this is the natural end of their life (6.3%), but 38.4% of respondents thought that the NHS should 
give priority to patients expected to die soon if they die before the natural end of their life (Q4). 
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 However, more than half (55.3%) thought the NHS should give the same priority to all patients. So 
EOL matters to nearly half of the respondents and then only if it is before normal life expectancy. In 
question 5, only 3.9% of respondents thought the NHS should give priority to extending the life of 
patients expected to die soon even if they live in poor health. There were 56.4% of respondents who 
indicated that the NHS should give priority to extending the life of patients expected to die soon but 
only if it means they live in a reasonable level of health, while 39.7% of respondents thought that the 
NHS should give the same priority to all patients. In this latter case, EOL was important but only 
where the patients lived in reasonable health. When the choice was between EOL and treatment 
gain, 88% of respondents chose to give priority to largest treatment gain over EOL (Q7).  
 
Question 5 was used to assess whether the attitudes were consistent with the DCE results, where 
the regression involving QALY, QALY squared and EOL was re-estimated on subsamples generated 
using their responses to question 5. As would be expected, the EOL coefficient was larger for those 
who show a preference towards EOL compared to those who did not (Appendix 3 Table 2).  
 
3.5.3 Therapeutic improvement (TI) 
Only 8.1% of respondents thought that the NHS should give priority to treatments with large 
treatment gain for a small number of patients. There were 82.4% of respondents who indicated that 
the NHS should consider the amount of benefit overall rather than considering how it is shared out 
among different numbers of patients, again suggesting a preference for QALY maximisation.  
 
Question 6 was used to assess whether the attitudes were consistent with the DCE results. 
Regressions involving QALY, QALY squared and BOI were re-estimated on subsamples generated 
using question 6. There were small differences across the 3 groups representing those who had a 
preference for concentration, dispersion or no preference for either (Appendix 3, Table 3). However, 
given the small numbers of respondents in the first two groups, these results may be driven by the 
size and composition of profiles in the smaller samples so they should be treated with caution. 
Overall the responses to these questions indicated that most respondents believed that the NHS 
should give preference to the group with the largest treatment gain over BOI or EOL. The results 
suggest some support for BOI, though this depended on the size of treatment gain and some support 
for EOL provided they live at a reasonable level of health. There is very little support for TI. However 
it must be remembered that these are dichotomous questions and do not permit trading-off 
between attributes. A large proportion of respondents consistently indicated that the same priority 
should be given to all patients indicating that they were not QALY maximisers.  
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3.5.4 Robustness of results 
Comparing responses to the attitudinal questions for respondents who misunderstood the DCE 
analysis (see section 3.4.6) and the remaining respondents showed that a large proportion of 
respondents who misunderstood the DCE task chose that the NHS should give the same priority to 
treating all patients, regardless of how ill they are or when they will die. In contrast, the percentage 
of respondents expressing a preference for BOI and EOL was higher for the remaining sample of 
respondents than for respondents who misunderstood the DCE task. The responses to the 
attitudinal questions were therefore consistent with the regression results excluding the 
respondents who seemed to have misunderstood the DCE task. 
4 DISCUSSION 
4.1 Summary 
This was the first study to examine societal preferences over BOI alongside TI and EOL. It was a large 
DCE survey using an existing online panel drawn from the general population. The results confirmed 
that respondents took into account the profile information provided in the text in the expected way 
i.e. they were more likely to choose profiles with lower life expectancy and HRQoL before treatment 
(severe health) and profiles with higher life expectancy and HRQoL after treatment (larger gains). 
The key findings in policy terms were that survey participants preferred to treat patients who had 
larger QALY gains but at a diminishing rate, meaning there was no support for TI. They also preferred 
to treat patients who had a shorter life expectancy or who were at the end of life (EOL). The results 
for BOI were less robust across versions of the questionnaire but suggested some modest support 
for BOI. Regressions excluding respondents who seemed to have misunderstood the DCE task found 
larger and more robust support for BOI. The attitudinal questions seemed to support the regression 
results for QALY gains and BOI although less so for EOL. The attitude questions also indicated that 
many respondents preferred to treat all patients the same, though the meaning of this response is 
unclear. 
 
4.2 QALY gains and therapeutic improvement 
The results of this survey indicated that respondents tend to choose to treat the group with the 
larger treatment gain, but they did not support the notion of TI (QALY squared) set out in the value 
based pricing consultation document.[DH, 2010] The negative QALY squared term indicated a 
diminishing marginal gain with each increase in QALYs. All other things being equal, there was a 
49 
 switching point where the impact of further QALY gains became negative overall. This indicated a 
point where there was a preference for smaller gains over larger gains. The precise point of this 
switch was specific to each questionnaire variant. Although the model with the QALY squared term 
fitted the data better statistically, it may not be representative of societal preferences but rather 
may be as a result of the study design. QALY gains were heavily skewed towards smaller gains with 
few scenarios with large QALY gains and this may have had an effect on the results. However, 
though it is not directly comparable in terms of the attributes included, Lancsar et al.[2011] found 
QALY gains to have a positive and statistical impact but again at a declining rate, as did a recent 
study by Norman et al.,[2012] with both rejecting the notion of TI. The application of this declining 
weight on QALY gain could have a major impact on health care policy making.  
 
4.3 End of life  
The regression results showed that there was support for EOL across the regression models, with 
evidence for a preference to treat those who were at the end of their life. Although responses to the 
attitude questions cast some doubt on this finding, as this was not a view held by the majority, 
testing the DCE results based on attitudes indicated that those whose attitudes supported EOL also 
had larger coefficients for EOL in the DCE. While size of treatment effect was more important than 
EOL, it does not mean that EOL had no value. It should be noted that the current NICE criteria for 
EOL also states that the condition should be rare,[NICE, 2009] but rarity was not examined in this 
study. 
 
4.4 Burden of illness 
The findings from the attitude questions and the DCE suggested some support for BOI, though the 
findings were not consistent across all models estimated using all responses. The responses to 
practice question 2 found little support for BOI across all respondents with between 46.8% and 
54.3% of respondents across variants choosing the option with higher BOI. However, excluding 
respondents who misunderstood the DCE task indicated that remaining respondents had a clear 
preference for BOI (63.5%). This provided support that BOI did have a positive impact overall.  
 
BOI provided a broader notion of severity than previous research since it incorporated the impact on 
QoL and length of life over the patient’s future life. The impact of BOI was quite modest, though 
significant, in three of the four normal life expectancy groups when estimated using all responses, 
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 but was always larger and significant in regressions across all variants excluding respondents who 
misunderstood the DCE task.  
Splitting the BOI term indicated that the small positive coefficient in the BOI term was a result of 
different effects of burden from poor HRQoL (BOIQL) and burden from shorter life expectancy 
(BOISU). The latter was as expected and was positive indicating that respondents were more likely to 
choose profiles with higher QALY loss from shorter life expectancy. The negative coefficients on 
BOIQL would seem to contradict the severity argument (which implies that lower pre-treatment 
HRQoL should increase the weight given to a given BOIQL), since the negative coefficients implied 
respondents preferred to treat those in less severe health in HRQoL terms. However, BOIQL was not 
solely attributable to HRQoL, since it was the result of the product of pre-treatment HRQoL and 
survival. BOIQL can increase due to either a reduction in HRQoL (i.e. H) or an increase in pre-
treatment survival. Therefore, BOIQL cannot be seen as a test of the conventional severity 
argument. Equally this suggests that BOI cannot be split into a HRQoL effect and a survival effect, 
since by definition BOI is composed of both. Regressions estimated excluding respondents who 
misunderstood the DCE task had positive and significant coefficients for BOISU and BOIQL (except 
the coefficient for BOIQL was not significant for the 80 year variant).  
 
The coefficients for BOI were not consistent across the four normal life expectancies and did not 
seem to exhibit an obvious pattern. Conversely, the coefficient for the QALY term declined with 
normal life expectancy. Standardising the BOI and QALY terms did improve the performance of the 
model in the pooled data, but it did not stabilise the BOI coefficients across the life expectancies. 
The main results do not support the notion of a proportional shortfall approach to BOI proposed by 
Stolk et al.[2005] However, the regressions estimated excluding respondents who misunderstood 
the DCE task are more consistent with the proportional shortfall approach as the coefficients for the 
standardised BOI terms are more similar across the variants. The experiment by Stolk and colleagues 
was different to the DCE used here since it assumed a magic pill that restored someone to full health 
and normal life expectancy. 
 
4.4.1  Life expectancy, end of life and health related quality of life 
The results from the models involving HRQoL before (H) and after (HQ) treatment and life 
expectancy before (E) and after (ES) treatment provided the best performing models. In contrast to 
above, respondents choose profiles with lower HRQoL before treatment. Further analysis to assess 
this based on life expectancy and HRQoL before treatment (E and H) indicated that when included 
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 with the QALY term, E remained negative but H was positive. Estimating the overall impact of E and 
H in that model (since they also appear in the QALY terms), resulted in them remaining negative and 
positive respectively. This may mean that respondents did not take into account severity in HRQoL in 
the expected way. However, there were no scenarios where conditions A and B differed solely on 
the basis of HRQoL before treatment, so it is difficult to make any conclusions regarding the impact 
of this on preferences. This would seem to contradict the evidence on the impact of severity defined 
in terms of low pre-treatment HRQoL on social preferences, but many of these used different 
methods and were often substantially smaller in scale than this one.[Shah, 2009] Other recent large 
scale studies with members of the general population, including Lancsar et al.[2011] in the UK and 
Norman et al.[2012] in Australia found respondents were less likely to choose patient groups with a 
higher HRQoL loss which is consistent with the current findings. However, when respondents who 
misunderstood the DCE task were excluded from the analyses, coefficients for H and E were both 
negative and significant, suggesting that the results in the main analysis may have been due to the 
inclusion of respondents who misunderstood the DCE task. 
 
4.5 Normal life expectancy (N) 
Overall, the results indicated that normal life expectancy in the profiles (N) had an effect on the 
results with decreasing coefficient size on gains in life years as normal life expectancy increased. This 
effect was also present on life expectancy without treatment and QALY gains and BOI to a lesser 
extent. The largest impact of varying life expectancy was between 5 years and 20 years. 
Standardisation indicated that scale may have been an issue for the QALY and survival terms, and 
BOI in regressions excluding respondents who seemed to have misunderstood the DCE task, since 
much of the difference was removed. However, the standardisation of the variables did not 
completely eradicate this effect, meaning that other factors may have affected the results and 
absolute values may have continued to have a role. This is an important finding as it indicates that 
framing may affect results even when respondents see a single life expectancy as has been used in 
other studies that have followed a similar approach (e.g. Shah et al. 2012).  
 
4.6 Existing literature 
Since the start of this project two large studies have been conducted examining preferences for 
value based pricing. These recently conducted surveys in the literature support the current findings 
for BOI and TI but not for EOL. Linley and Hughes[2013] conducted an online survey of 4,118 UK 
general population asking respondents how they would prefer NHS money to be spent across two 
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 groups of patients, where a scale was provided that meant if they chose to treat more patients in 
one group fewer patients were treated in the other group. Attributes were varied across the two 
groups of patients including severity of disease and EOL. The sample was split into two cohorts 
where further questions examining preferences were used. The first cohort was asked the same 
question but where treatment improves health a little for patients with severe disease but 
considerably for patients with moderate disease. The second cohort was asked the same question 
but treatment costs differ across the groups where treating patients with the severe disease has 
double costs in comparison to patients with moderate disease. The study found that there was a 
societal preference for the allocation of NHS funds to treat patients with severe rather than 
moderate disease, but not for treating patients with EOL. This is contrary to the results found in the 
current survey regarding EOL. The framing of the Linley and Hughes[2013] survey was very different 
to the framing of the current survey, and it is possible that this influenced the results. In particular 
the first cohort were asked a question combining size of QALY gain and severity or EOL, and the 
second cohort were asked to consider costs, whereas costs are not mentioned in the current survey.  
 
In a small exploratory study (n=50) to assess the impact of EOL, Shah et al.[2013] found weak 
support for treating EOL patients while a larger follow-on study indicated little support for EOL.[Shah 
et al, 2012] The difference in preferences for EOL for the current survey and the larger follow-on 
survey is surprising given that both used a similar question format to elicit preferences (the Shah et 
al. 2012 survey used study 2 described above to inform the design of their survey), though framing 
effects obviously remain. The Shah et al.[2012] study involved an online survey of 3,969 UK 
respondents asking which of two hypothetical patients should be treated, where the health service 
has enough funds to treat one patient but not both. Respondents were provided information on the 
life expectancy and quality of life of the patients without treatment, and life expectancy and quality 
of life gains from treatment. In contrast to the current survey, respondents were not provided with 
any information about normal life expectancy and quality of life if the patient did not have the 
condition. Whilst the study indicated little support for EOL, the size of the QALY gains were found to 
be important and this is consistent with the findings regarding QALY gains in the current study. 
 
4.7 Limitations 
A concern with this survey is the use of an online sample, since it may exclude groups in society such 
as the computer illiterate or those unable to access a computer. The use of an online panel means 
that respondents have stated that they are willing to regularly answer online surveys, and this also 
makes them unrepresentative of computer users. As the respondents receive points for every survey 
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 they complete that can be exchanged for goods this also may lead to the reasoning for answering 
the survey to be questioned, and may again indicate that these respondents are not representative 
of the UK. The importance of these selection processes for the responses obtained in the survey is 
not known. However, the sample was recruited using a nationally representative quota for age and 
gender and for these characteristics the sample is nationally representative. 
 
Preparatory studies undertaken before the main survey suggested that some respondents failed to 
understand the tasks set. The main survey was therefore designed to minimise this problem and 
comprised: an introduction video, 2 practice questions with feedback and profiles that included 
pictures to aid understanding. Respondents’ views of the survey indicated that the majority of 
respondents did not find either the DCE tasks or the attitudinal questions difficult. However there 
was evidence to suggest that respondents did not always understand the DCE tasks, where 
respondents failed to select to treat the patients who were most deserving of treatment. Some 
respondents failed to understand that the task asked them to choose which patient group to treat, 
as they chose the better health profile in overall QALY terms, not the profile with the patients who 
were most deserving of treatment in terms of BOI and QALY gains.  
 
Respondents who chose a profile that had a higher number of total lifetime QALYs after treatment, 
but smaller QALY gain from treatment and lower BOI before treatment than the other profile were 
therefore excluded in robustness analyses. The exclusion of these respondents could be criticised on 
the grounds that it was imposed after the data were collected. Although a large number of 
respondents are excluded using this criterion, this is not a reason for including respondents who 
misunderstood the tasks as their responses are not random and show a preference for the better 
profile rather than the patients they wish to treat. However, it is possible that some of these 
respondents did understand the task and were expressing a genuine preference, though this is 
unlikely given the response. Qualitative work would be required to ascertain the full nature and 
extent of the understanding of the task and this was not undertaken in this study. The exclusion of 
individuals who misunderstood the DCE task in robustness analyses did not affect the significance 
and direction of terms representing QALY gains, TI and EOL, but for BOI the coefficients were larger 
and the sign consistent across the variants. 
 
While there is no explicit reference to age in the questions, it could be argued that respondents 
would be able to estimate the age of the recipients of the treatment from the normal life 
expectancies. However, this did not come up in preparatory study 3, a small qualitative survey, 
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 where respondents were asked what they were thinking about as they were completing the task. 
Furthermore, each respondent only faced one normal life expectancy and so the survey did not draw 
attention to this feature. The results by subgroup did find differences across the four life 
expectancies, which were substantially reduced when standardisation was carried out. This indicates 
that life expectancy influenced results but it is not possible to verify whether respondents were 
thinking about age or other factors such as end of life when they were faced with the fixed life 
expectancy.  
 
The study assumes that respondents have a zero time preference, but it is possible that this 
assumption may not be correct. Whilst societal time preferences may not be as large as individual 
time preferences, this remains a limitation of the study. 
 
The attitudinal questions suffer from the limitation that they are dichotomous and do not address 
trade-offs between attributes. The format of these questions may mean that respondents state that 
all patients should be treated the same while their response may have been different if a trade-off 
had been required. In contrast the DCE tasks require a choice and do not allow respondents to state 
that they are indifferent, or in effect that they wish to treat all respondents the same. However, it is 
expected that these respondents will randomly choose to treat either of the patient groups and 
hence this will not affect the regression results.  
5 CONCLUSION 
This study provides the first attempt to operationalise the concept of BOI which combines the 
conventional notion of severity (in terms of low HRQoL) with survival (using QALY loss from the 
condition) to provide an indicator of the severity of a condition. It also provides evidence on societal 
preferences for EOL and the size of the gain (TI). The results indicate some support for BOI as a 
consideration when weighting QALYs, but it seems to be driven by burden from premature mortality 
rather than morbidity. The evidence did not support the idea of TI. There was robust and consistent 
support for EOL in general. Overall there seems to be a strong preference for larger QALY gain but at 
a diminishing rate. These results support the argument that the social value of a QALY is not equal 
between recipients and depends on both the burden of their condition and expected survival. 
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 7 Appendix  
Appendix 1: Standardised descriptive statistics 
 
Appendix 1 Table 1: Mean standardised values across the questionnaire variants       
version    stdH stdQ stdE stdS stdHQ stdES stdQALY stdBOI stdQLYSU stdQLYQL stdBOISU stdBOIQL 
             5 yrs 0.41638 0.18271 0.24111 0.14816 0.59909 0.38926 0.1346 0.90135 0.088362 0.046236 0.75889 0.14245 
20 yrs 0.41111 0.1719 0.18105 0.12305 0.583 0.3041 0.10196 0.92588 0.070834 0.031128 0.81895 0.10693 
40 yrs 0.41476 0.17429 0.21664 0.06254 0.58905 0.27918 0.07529 0.91218 0.036562 0.038731 0.78336 0.12882 
80 yrs 0.41159 0.17132 0.19499 0.12932 0.58291 0.32431 0.10637 0.91686 0.072397 0.033973 0.80501 0.11185 
 
Appendix 1 Table 2: Range (maximum - minimum) standardised values across the questionnaire variants 
version stdH stdQ stdE stdS stdHQ stdES stdQALY stdBOI stdQLYSU stdQLYQL stdBOISU stdBOIQL 
             5 yrs 0.7 0.6 0.95 0.6 0.9 0.95 0.679 0.795 0.6 0.6 0.95 0.89 
20 yrs 0.7 0.6 0.4875 0.5 0.9 0.9875 0.79938 0.39875 0.5 0.3 0.4875 0.4475 
40 yrs 0.7 0.6 0.74375 0.25 0.9 0.99375 0.52487 0.59938 0.25 0.45 0.74375 0.67375 
80 yrs 0.7 0.6 0.74687 0.75 0.9 0.87187 0.78744 0.59969 0.75 0.45 0.74687 0.67438 
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 Appendix 2: Results excluding respondents who misunderstood the DCE task 
 
Appendix 2 Table 1: Summary of excluded respondents who misunderstood the DCE task and 
respondents in the remaining sample 
 All 
respondents 
Excluded respondents 
who arguably 
misunderstood 
Remaining 
sample 
analysis 
England * 
n 3,669 1,422 2,247  
Mean age (s.d.) 46.5 (16.6) 48.6 (16.2) 45.1 (16.8) NA 
Age distribution     
       18-40 39.9% 34.6% 43.2% 41.6% 
       41-65 42.1% 44.7% 40.5% 39.1% 
       Over 65 18.0% 20.7% 16.3% 19.3% 
Female 54.3% 54.0% 54.5% 51.3% 
Married/Partner 62.4% 64.8% 60.8% NA 
Employed or self-employed 47.3% 46.5% 47.9% 60.9% 
Unemployed 6.2% 5.8% 6.4% 3.4% 
Long-term sick 6.4% 7.3% 5.8% 5.3% 
Full-time student 7.2% 4.9% 8.7% 7.3% 
Retired 23.8% 26.7% 22.0% 13.5% 
Secondary school is highest level of 
education 
21.6% 26.4% 18.6%  
Degree or equivalent professional 
qualification 
48.2% 47.0% 49.0%  
Health in general is very good or 
good 
66.9% 63.7% 68.9%  
Limited by long term health 
   
37.0% 41.4% 34.2%  
EQ-5D score, mean (s.d.) 0.78 (0.26) 0.76 (0.28) 0.80 (0.25) 0.86 
 Experienced serious illness in 
yourself 
33.6% 36.2% 32.0%  
Experienced serious illness in family 74.5% 75.1% 74.2%  
Experienced serious illness in caring 
for others 
33.5% 34.7% 32.7%  
Found DCE questions quite or very 
difficult to understand 
7.6% 8.9% 6.8%  
Found attitudinal questions quite or 
very difficult to understand 
6.6% 7.7% 5.9%  
Median completion time in minutes 
from consent to end of survey 
(Interquartile range) 
21 (17-27) 20 (17-26) 22 (17-28)  
Notes: * Statistics for England in the Census 2001. Questions used in this study and the census are not identical. The census 
includes persons aged 16 and above whereas this study only surveys persons aged 18 and above. Age distribution is here 
reported as the percentage of all adults aged 18 and over. 
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 Appendix 2 Table 2: Responses to practice questions for excluded respondents who misunderstood 
the DCE task and respondents in the remaining sample 
Practice 
Question 
Respondents Practice question  
First response 
Practice question  
Second response 
Practice question  
Final response 
  n A B n A B n A B 
1 All 
respondents 
3,669 8.3% 91.7% 179 22.3% 77.7% 3,669 7.0% 93.0% 
 Excluded 
respondents 
1,422 10.1% 89.9% 72 19.4% 80.6% 1,422 8.7% 91.4% 
 Remaining 
sample 
2,247 7.1% 92.9% 107 24.3% 75.7% 2,247 6.0% 94.0% 
2 All 
respondents 
3,669 46.8% 53.2% 252 67.1% 32.9% 3,669 50.8% 49.3% 
 Excluded 
respondents 
1,422 27.9% 72.2% 88 55.7% 44.3% 1,422 30.6% 69.4% 
 Remaining 
sample 
2,247 58.7% 41.3% 164 73.2% 26.8% 2,247 63.5% 36.5% 
Notes: Respondents who stated after the explanation of their choice that they did not still want to treat the same group 
were asked the question again, and this process was repeated allowing respondents up to 7 attempts in total before 
moving on to the next question. 
 
Appendix 2 Table 3: HRQoL and life expectancy before and after treatment excluding respondents 
who misunderstood the DCE task 
Variables All 5 years 20 years 40 years 80 years 
H -0.051881*** -0.064297*** -0.052721*** -0.061813*** -0.051130*** 
 (0.000) (0.000) (0.000) (0.000) (0.000) 
E -0.136811*** -1.486658*** -0.411863*** -0.250984*** -0.050154*** 
 (0.000) (0.000) (0.000) (0.000) (0.000) 
HQ 0.057180*** 0.069305*** 0.058699*** 0.060395*** 0.060320*** 
 (0.000) (0.000) (0.000) (0.000) (0.000) 
ES 0.130886*** 1.432319*** 0.359007*** 0.225150*** 0.050150*** 
 (0.000) (0.000) (0.000) (0.000) (0.000) 
Log likelihood -12107 -3244 -2090 -2536 -3160 
Rho-squared 0.223 0.325 0.280 0.264 0.286 
AIC 24222 6496 4188 5080 6327 
BIC 24257 6526 4217 5109 6357 
Mean VIF 2.10 2.13 1.85 5.61 1.76 
stdH -5.750397*** -6.429696*** -5.272089*** -6.181328*** -5.113010*** 
 (0.000) (0.000) (0.000) (0.000) (0.000) 
stdE -6.899348*** -7.433292*** -8.237261*** -10.039367*** -4.012287*** 
 (0.000) (0.000) (0.000) (0.000) (0.000) 
stdHQ 6.252886*** 6.930519*** 5.869880*** 6.039451*** 6.031969*** 
 (0.000) (0.000) (0.000) (0.000) (0.000) 
stdES 6.456234*** 7.161597*** 7.180147*** 9.006004*** 4.012018*** 
 (0.000) (0.000) (0.000) (0.000) (0.000) 
Observations 44,940 13,860 8,380 9,940 12,760 
Log likelihood -11159 -3244 -2090 -2536 -3160 
Rho-squared 0.284 0.325 0.280 0.264 0.286 
AIC 22327 6496 4188 5080 6327 
BIC 22362 6526 4217 5109 6357 
Mean VIF 2.07 2.13 1.85 5.61 1.76 
Observations 44,940 13,860 8,380 9,940 12,760 
pval in parentheses; *** p<0.01, ** p<0.05, * p<0.1; H and E HRQoL and life expectancy before treatment; HQ and ES 
HRQoL and life expectancy after treatment 
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 Appendix 2 Table 4: QALY gains and life expectancy before treatment/end of life excluding 
respondents who misunderstood the DCE task 
Variables All 5 years 20 years 40 years 80 years 
QALY 0.378105*** 4.199664*** 1.024335*** 0.574489*** 0.232746*** 
 (0.000) (0.000) (0.000) (0.000) (0.000) 
QALY_sq -0.005354*** -0.853617*** -0.052240*** -0.017664*** -0.003016*** 
 (0.000) (0.000) (0.000) (0.000) (0.000) 
E -0.051728*** -0.430212*** -0.177651*** -0.089013*** -0.027102*** 
 (0.000) (0.000) (0.000) (0.000) (0.000) 
Log likelihood -12670 -3266 -2049 -2616 -3252 
Rho-squared 0.186 0.320 0.295 0.241 0.265 
AIC 25347 6538 4103 5239 6509 
BIC 25373 6560 4124 5260 6532 
Mean VIF 6.27 7.00 5.08 5.22 8.02 
stdQALY 20.232614*** 20.998320*** 20.486696*** 22.979556*** 18.619662*** 
 (0.000) (0.000) (0.000) (0.000) (0.000) 
stdQALY_sq -21.164541*** -21.340418*** -20.896071*** -28.262211*** -19.301296*** 
 (0.000) (0.000) (0.000) (0.000) (0.000) 
stdE -2.762355*** -2.151060*** -3.553029*** -3.560510*** -2.168166*** 
 (0.000) (0.000) (0.000) (0.000) (0.000) 
      
Log likelihood -11254 -3266 -2049 -2616 -3252 
Rho-squared 0.277 0.320 0.295 0.241 0.265 
AIC 22514 6538 4103 5239 6509 
BIC 22540 6560 4124 5260 6532 
Mean VIF 5.93 7.00 5.08 5.22 8.02 
QALY 0.307749*** 3.296674*** 0.914302*** 0.492998*** 0.187517*** 
 (0.000) (0.000) (0.000) (0.000) (0.000) 
QALY_sq -0.004281*** -0.640304*** -0.045515*** -0.017628*** -0.002328*** 
 (0.000) (0.000) (0.000) (0.000) (0.000) 
EOL_3mth 1.189960*** 1.053927*** 1.326816*** 1.326196*** 0.704581*** 
 (0.000) (0.000) (0.000) (0.000) (0.000) 
Log likelihood -12480 -3254 -2004 -2708 -3358 
Rho-squared 0.199 0.323 0.310 0.214 0.241 
AIC 24966 6515 4014 5421 6723 
BIC 24992 6537 4035 5443 6745 
Mean VIF 5.42 7.85 4.99 5.13 7.42 
stdQALY 16.354869*** 16.483372*** 18.286034*** 19.719938*** 15.001385*** 
 (0.000) (0.000) (0.000) (0.000) (0.000) 
stdQALY_sq -16.615309*** -16.007599*** -18.205976*** -28.204049*** -14.900992*** 
 (0.000) (0.000) (0.000) (0.000) (0.000) 
EOL_3mth 1.081820*** 1.053927*** 1.326816*** 1.326196*** 0.704581*** 
 (0.000) (0.000) (0.000) (0.000) (0.000) 
Log likelihood -11402 -3254 -2004 -2708 -3358 
Rho-squared 0.268 0.323 0.310 0.214 0.241 
AIC 22811 6515 4014 5421 6723 
BIC 22837 6537 4035 5443 6745 
Mean VIF 5.62 7.85 4.99 5.13 7.42 
Observations 44,940 13,860 8,380 9,940 12,760 
pval in parentheses; *** p<0.01, ** p<0.05, * p<0.1; QALY – QALY gains from new treatment; QALY_sq – QALY squared 
E –life expectancy before treatment; EOL – life expectancy before treatment ≤2 years and with survival gains≥ 3 months 
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 Appendix 2 Table 5: QALY gains with life expectancy and HRQoL before treatment excluding 
respondents who misunderstood the DCE task 
Variables All 5 years 20 years 40 years 80 years 
QALY 0.384801*** 4.641321*** 1.054246*** 0.642400*** 0.238122*** 
 (0.000) (0.000) (0.000) (0.000) (0.000) 
QALY_sq -0.005436*** -0.948974*** -0.053376*** -0.020285*** -0.003071*** 
 (0.000) (0.000) (0.000) (0.000) (0.000) 
E -0.052735*** -0.483926*** -0.181264*** -0.098784*** -0.027816*** 
 (0.000) (0.000) (0.000) (0.000) (0.000) 
stdH -0.296948*** -1.278359*** -0.578428*** -1.562883*** -0.429257*** 
 (0.000) (0.000) (0.000) (0.000) (0.000) 
Log likelihood -12654 -3202 -2038 -2537 -3243 
Rho-squared 0.188 0.333 0.298 0.264 0.267 
AIC 25316 6413 4083 5082 6494 
BIC 25351 6443 4112 5111 6524 
Mean VIF 4.96 5.53 4.06 4.22 6.39 
stdQALY 21.376507*** 23.206606*** 21.084918*** 25.696004*** 19.049750*** 
 (0.000) (0.000) (0.000) (0.000) (0.000) 
stdQALY_sq -22.277241*** -23.724347*** -21.350448*** -32.455529*** -19.651769*** 
 (0.000) (0.000) (0.000) (0.000) (0.000) 
stdE -2.932246*** -2.419631*** -3.625283*** -3.951376*** -2.225241*** 
 (0.000) (0.000) (0.000) (0.000) (0.000) 
stdH -0.885604*** -1.278359*** -0.578428*** -1.562883*** -0.429257*** 
 (0.000) (0.000) (0.000) (0.000) (0.000) 
Log likelihood -11133 -3202 -2038 -2537 -3243 
Rho-squared 0.285 0.333 0.298 0.264 0.267 
AIC 22274 6413 4083 5082 6494 
BIC 22308 6443 4112 5111 6524 
Mean VIF 4.70 5.53 4.06 4.22 6.39 
Observations 44,940 13,860 8,380 9,940 12,760 
pval in parentheses; *** p<0.01, ** p<0.05, * p<0.1; QALY – QALY gains from new treatment; QALY_sq – QALY squared; H 
and E – HRQoL and life expectancy before treatment 
Notes: stdH i.e. H/100 is used in the unstandardized QALY model to reflect the fact that H/100 is used to build the QALY. 
This has no effect on the direction of the coefficient; it just increases the magnitude by a factor of 100. 
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 Appendix 2 Table 6: Summary of response to attitudinal questions for excluded respondents who misunderstood the DCE task and respondents in the 
remaining sample 
 Normal life expectancy All 
respondents 
Excluded 
respondents 
Remaining 
sample 
Question Response 3,669 1,422 2,247 
 BOI    
1  The NHS should give priority to treating patients who are very ill 40.7% 34.2% 44.8% 
 The NHS should give the same priority to treating all patients who are ill, regardless of how ill they are 59.3% 65.8% 55.2% 
2 The NHS should give priority to treating patients who are very ill and will die early because of their illness 42.5% 35.2% 47.1% 
 The NHS should give the same priority to treating all patients who are ill, regardless of how ill they are or when 
they will die 
57.5% 64.8% 52.9% 
3 The NHS should always give priority to treating patients who are very ill and will die early because of their 
illness, even if they only get a small amount of benefit from treatment 
9.5% 9.4% 9.7% 
 The NHS should give priority to treating patients who are very ill and will die early because of their illness, but 
only if they get a large amount of benefit from treatment 
44.4% 38.3% 48.3% 
 The NHS should give the same priority to treating all patients, regardless of how ill they are or when they will 
die 
46.1% 52.4% 42.0% 
8 The NHS should give priority to treating patients who are very ill and will die early because of their illness 10.6% 8.4% 12.0% 
 The NHS should give priority to treating patients who will get the largest amount of benefit from treatment 44.6% 41.4% 46.7% 
 The NHS should give the same priority to treating all patients 44.8% 50.2% 41.3% 
 EOL    
4 The NHS should give priority to extending the life of patients who are expected to die soon, even if this is the 
natural end of their life 
6.3% 7.5% 5.5% 
 The NHS should give priority to patients expected to die soon, but only if it means they die before the natural 
end of their life 
38.4% 30.7% 43.3% 
 The NHS should give the same priority to treating all patients, regardless of how ill they are or when they will 
die 
55.3% 61.8% 51.2% 
5 The NHS should give priority to extending the life of patients who are expected to die soon, even if this means 
they live in very poor health 
3.9% 4.1% 3.7% 
 The NHS should give priority to extending the life of patients who are expected to die soon, but only if they 
would live in a reasonable level of health 
56.4% 50.2% 60.3% 
 The NHS should give the same priority to treating all patients, regardless of how ill they are or when they will 
die 
39.7% 45.7% 36.0% 
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  Normal life expectancy All 
respondents 
Excluded 
respondents 
Remaining 
sample 
Question Response 3,669 1,422 2,247 
7 The NHS should give priority to extending the life of patients expected to die soon 12.0% 10.8% 12.8% 
 The NHS should give priority to treating patients who will get the largest amount of benefit from treatment 88.0% 89.2% 87.2% 
 Therapeutic Improvement    
6 The NHS should give priority to treatments that give a large amount of benefit to a small number of patients 8.1% 8.9% 7.7% 
 The NHS should give priority to treatments that give a small amount of benefit to a large number of patients 9.5% 11.3% 8.3% 
 The NHS should consider the amount of benefit a treatment gives overall, rather than considering how it is 
shared out among different numbers of patients 
82.4% 79.8% 84.0% 
 Combined     
9 The NHS should give priority to treating patients who are very ill and will die early because of their illness 13.1% 11.0% 14.4% 
 The NHS should give priority to treating patients who will get the largest amount of benefit from treatment 52.1% 48.5% 54.4% 
 The NHS should give priority to treating patients who will live for a long time and be in good health after 
treatment 
34.8% 40.5% 31.2% 
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 Appendix 3: Analysis on attitudinal questions and DCE responses 
 
Appendix 3 Table 1: Test attitude question 2 [Burden 42% vs. All the same 58%] 
 Variables All 5yrs 20yrs 40yrs 80yrs 
Prefer BOI QALY 0.263849*** 3.750114*** 0.798500*** 0.386393*** 0.166535*** 
  (0.000) (0.000) (0.000) (0.000) (0.000) 
 QALY_sq -0.003709*** -0.717338*** -0.041634*** -0.013412*** -0.002048*** 
  (0.000) (0.000) (0.000) (0.000) (0.000) 
 BOI 0.036957*** 0.350807*** 0.059065*** 0.055351*** 0.021540*** 
  (0.000) (0.000) (0.002) (0.000) (0.000) 
       
 Observations 31,160 8,600 6,320 7,700 8,540 
 Log likelihood -9356 -2163 -1680 -2300 -2375 
 Rho-squared 0.134 0.274 0.233 0.138 0.198 
       
Same Priority  QALY 0.288450*** 3.591170*** 0.720589*** 0.420029*** 0.177417*** 
regardless of  (0.000) (0.000) (0.000) (0.000) (0.000) 
BOI QALY_sq -0.003964*** -0.707044*** -0.034468*** -0.014630*** -0.002087*** 
  (0.000) (0.000) (0.000) (0.000) (0.000) 
 BOI 0.000810 -0.052535 -0.040132*** 0.025085*** -0.010099*** 
  (0.731) (0.196) (0.010) (0.000) (0.000) 
       
 Observations 42,220 11,840 8,880 10,080 11,420 
 Log likelihood -12343 -2975 -2353 -2932 -2996 
 Rho-squared 0.156 0.275 0.235 0.161 0.243 
pval in parentheses; *** p<0.01, ** p<0.05, * p<0.1 
 
Question 2 : The NHS should All 5 20 40 80 
give priority to treating patients who are very ill and will die early because of their illness 42.5% 42.1% 41.6% 43.3% 42.8% 
give the same priority to treating all patients who are ill, regardless of how ill they are or when they will die 57.5% 57.9% 58.4% 56.7% 57.2% 
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 Appendix 3 Table 2: Test attitude question 5 (Preference for those at EOL 60% vs. Same priority 40%) 
 
 Variables All 5yrs 20yrs 40yrs 80yrs 
Prefer to treat QALY 0.289660*** 3.465257*** 0.790120*** 0.432395*** 0.173923*** 
those at EOL  (0.000) (0.000) (0.000) (0.000) (0.000) 
 QALY_sq -0.004004*** -0.645310*** -0.038083*** -0.014956*** -0.002062*** 
  (0.000) (0.000) (0.000) (0.000) (0.000) 
 EOL 0.713568*** 0.746571*** 0.419514*** 0.733828*** 0.453378*** 
  (0.000) (0.000) (0.000) (0.000) (0.000) 
 Observations 44,220 12,120 9,320 10,860 11,920 
 Log likelihood -12780 -2920 -2425 -3109 -3216 
 Rho-squared 0.166 0.305 0.249 0.174 0.221 
       
       
Same priority QALY 0.269786*** 2.937967*** 0.718618*** 0.359284*** 0.177529*** 
for all  (0.000) (0.000) (0.000) (0.000) (0.000) 
 QALY_sq -0.003779*** -0.546943*** -0.034800*** -0.012604*** -0.002207*** 
  (0.000) (0.000) (0.000) (0.000) (0.000) 
 EOL 0.461005*** 0.432922*** 0.308074*** 0.355861*** 0.104242 
  (0.000) (0.000) (0.000) (0.000) (0.154) 
       
 Observations 29,160 8,320 5,880 6,920 8,040 
 Log likelihood -8613 -2170 -1581 -2081 -2171 
 Rho-squared 0.148 0.248 0.224 0.132 0.221 
pval in parentheses; *** p<0.01, ** p<0.05, * p<0.1 
 
 Question 5:The NHS should: All 5 20 40 80 
give priority to extending the life of patients who are expected to die soon 60.3% 59.3% 61.3% 61.1% 59.7% 
give the same priority to treating all patients, regardless of how ill they are or when they will die 39.7% 40.7% 38.7% 38.9% 40.3% 
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 Appendix 3 Table 3: Test attitude question 6 (Therapeutic improvement: Concentration 8% vs. dispersion 9% vs. overall QALY gain 82%) 
 Variables All 5yrs 20yrs 40yrs 80yrs 
Large amount QALY 0.222548*** 4.428066*** 0.608634*** 0.369315*** 0.131028*** 
benefit to small  (0.000) (0.000) (0.000) (0.000) (0.000) 
number of  QALY_sq -0.003153*** -0.960060*** -0.032567*** -0.013672*** -0.001584*** 
Patients  (0.000) (0.000) (0.000) (0.000) (0.000) 
(concentration) BOI 0.015528*** 0.246911** -0.028703 0.022020* 0.008351 
  (0.009) (0.030) (0.449) (0.072) (0.204) 
 Observations 5,980 1,800 1,240 1,580 1,360 
 Log likelihood -1867 -447.0 -357.5 -480.3 -403.9 
 Rho-squared 0.0992 0.283 0.168 0.123 0.143 
Small amount QALY 0.177368*** 1.700498*** 0.555886*** 0.257769*** 0.119564*** 
benefit to a   (0.000) (0.000) (0.000) (0.000) (0.000) 
large number of QALY_sq -0.002534*** -0.304565*** -0.026015*** -0.009224*** -0.001518*** 
patients   (0.000) (0.000) (0.000) (0.000) (0.000) 
(dispersion) BOI 0.003366 0.063837 -0.048391 0.046921*** -0.010773* 
  (0.491) (0.487) (0.143) (0.000) (0.055) 
 Observations 6,960 1,700 1,720 1,880 1,660 
 Log likelihood -2224 -528.2 -495.1 -605.7 -499.1 
 Rho-squared 0.0779 0.104 0.169 0.0704 0.132 
QALY benefit  QALY 0.297793*** 3.875474*** 0.803054*** 0.431632*** 0.181477*** 
Overall  (0.000) (0.000) (0.000) (0.000) (0.000) 
 QALY_sq -0.004107*** -0.745009*** -0.039694*** -0.014765*** -0.002145*** 
  (0.000) (0.000) (0.000) (0.000) (0.000) 
 BOI 0.019981*** 0.122691*** 0.013221 0.039859*** 0.006399*** 
  (0.000) (0.000) (0.333) (0.000) (0.002) 
 Observations 60,440 16,940 12,240 14,320 16,940 
 Log likelihood -17626 -4138 -3178 -4137 -4491 
 Rho-squared 0.159 0.295 0.251 0.166 0.235 
pval in parentheses; *** p<0.01, ** p<0.05, * p<0.1 
 
Question 6  - The NHS should: All 5 20 40 80 
give  priority to treatments that give a large amount of benefit to a small number of patients 8.1% 8.8% 8.2% 8.9% 6.8% 
give priority to treatments that give a small amount of benefit to a large number of patients 9.5% 8.3% 11.3% 10.6% 8.3% 
consider the amount of benefit a treatment gives overall, rather than considering how it is shared out among different nos. of 
patients 
82.4% 82.9% 80.5% 80.5% 84.9% 
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